medRxiv preprint doi: [https://doi.org/10.1101/2024.09.27.24314515;](https://doi.org/10.1101/2024.09.27.24314515) this version posted September 30, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

-
- $\frac{25}{4}$

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

26 **Abstract**
27 **Backgrou**
28 (UPF) int
29 UPF and 1
30 trial.
31 **Methods:**
32 followed
33 classificat

Background and Aims: There is limited evidence on the link between ultra-processed food

(UPF) intake and the risk of lung cancer (LC). This study examined the association between

UPF and LC risk using data from the Pr (UPF) intake and the risk of lung cancer (LC). This study examined the association between

29 UPF and LC risk using data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer

20 trial.

20 Methods: This study i 29 UPF and LC risk using data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer
20 trial.
20 trial.
20 Methods: This study involved PLCO participants (n = 96,607, aged \geq 55 years) who were
22 followed bet 30 trial.
31 **Meth**
32 follov
33 classi
34 (IPC'
35 effect
36 addit:
37 **Resu** 31 **Methods**: This study involved PLCO participants (n = 96,607, aged ≥ 55 years) who were
32 followed between 1998 and 2009. Food items were categorized based on the NOVA
33 classification. Cox regression models with in followed between 1998 and 2009. Food items were categorized based on the NOVA
classification. Cox regression models with inverse probability of censoring weighting
(IPCW) were utilized to estimate the association between U

classification. Cox regression models with inverse probability of censoring weighting

34 (IPCW) were utilized to estimate the association between UPF intake and LC risk. The joint

35 effect of UPF and diabetes was explor (IPCW) were utilized to estimate the association between UPF intake and LC risk. The joint

effect of UPF and diabetes was explored using additive hazard models to calculate the

additional number of LC cases.
 Results: 35 effect of UPF and diabetes was explored using additive hazard models to calculate the
36 additional number of LC cases.
37 **Results:** During a median follow-up period of 9.4 years, 1,596 incident LC cases were
38 ident additional number of LC cases.
 Results: During a median foll

identified. UPF consumption (

overall risk of LC. However, ad

significantly higher risk of LC

without diabetes. A small exces

42 95% CI -0.32, 0.58) was **Results:** During a median follow-up period of 9.4 years, 1,596 incident LC cases were
identified. UPF consumption (in %gram/day) showed no significant association with the
overall risk of LC. However, adults with diabete 38 identified. UPF consumption (in %gram/day) showed no significant association with the
39 overall risk of LC. However, adults with diabetes in the highest quintile of UPF intake had a
31 significantly higher risk of LC 39 overall risk of LC. However, adults with diabetes in the highest quintile of UPF intake had a

31 significantly higher risk of LC (HR = 2.44; 95% CI: 1.27, 4.67) compared to participants

31 without diabetes. A small e 40 significantly higher risk of LC (HR = 2.44; 95% CI: 1.27, 4.67) compared to participants
41 without diabetes. A small excess risk due to the interaction between UPF and diabetes (0.13;
42 95% CI: 0.32, 0.58) was observ 95% CI -0.32, 0.58) was observed, resulting in an additional 201 cases of LC per $10⁵$ person-

without diabetes. A small excess risk due to the interaction between UPF and diabetes (0.13;
42 95% CI -0.32, 0.58) was observed, resulting in an additional 201 cases of LC per 10^5 person-
928 years (95% CI: 70, 332) a 95% CI -0.32, 0.58) was observed, resulting in an additional 201 cases of LC per 10⁵ person-
years (95% CI: 70, 332) attributed to the highest UPF intake and diabetes interaction.
Furthermore, a 10% increment in UPF inta years (95% CI: 70, 332) attributed to the highest UPF intake and diabetes interaction.

Furthermore, a 10% increment in UPF intake (%kcal/day) increased the risk of LC by 32%.
 Conclusions: While UPF, in terms of weight Furthermore, a 10% increment in UPF intake (%kcal/day) increased the risk of LC by 32%.
 Conclusions: While UPF, in terms of weight contribution, is associated with a higher risk

LC in participants with diabetes, UPF (i **Conclusions**: While UPF, in terms of weight contribution, is associated with a higher risk of
LC in participants with diabetes, UPF (in %kcal/day), is associated with an increased risk of
LC in all participants. Lowering 46 LC in participants with diabetes, UPF (in %kcal/day), is associated with an increased risk of LC in all participants. Lowering UPF intake may help reduce the risk of LC in both diabetic patients and the general populati 47 LC in all participants. Lowering UPF intake may help reduce the risk of LC in both diabetic patients and the general population. 48 patients and the general population.

It is made available under a CC-BY-NC-ND 4.0 International license.

Key words: Ultra-processed food; incidence; lung cancer; older adult

10 Introduction

10 Interval of the most common an 50 **Introduction**
51 Lung cancer (1
52 incidence has
53 that approxima
54 die from the d
55 (DALYs) in b
56 all cancer deat
57 concern that d
58 Ultra-processe 51 Lung cancer (LC) is one of the most common and deadliest types of cancer worldwide and its
52 incidence has been increasing in many countries over the past few decades [1]. It is estimated
53 that approximately 2.3 mil incidence has been increasing in many countries over the past few decades [1]. It is estimated
that approximately 2.3 million people are diagnosed with LC each year, over 2 million people
die from the disease annually and that approximately 2.3 million people are diagnosed with LC each year, over 2 million people
die from the disease annually and LC accounts for 45.9 million disability-adjusted life years
(DALYs) in both sexes [2, 3]. LC is die from the disease annually and LC accounts for 45.9 million disability-adjusted life years

55 (DALYs) in both sexes [2, 3]. LC is the leading cause of cancer death, accounting for 23% of

56 all cancer deaths in Americ (DALYs) in both sexes [2, 3]. LC is the leading cause of cancer death, accounting for 23% of
56 all cancer deaths in America [4]. While smoking is the primary cause of LC, there is growing
57 concern that dietary factors m all cancer deaths in America [4]. While smoking is the primary cause of LC, there is growing
concern that dietary factors may also play a role in the development of the disease [5, 6].
Ultra-processed food (UPF) is typical concern that dietary factors may also play a role in the development of the disease [5, 6].

Ultra-processed food (UPF) is typically highly processed and contain a large numbe

additives, such as artificial flavours, colou

Ultra-processed food (UPF) is typically highly processed and contain a large number of
additives, such as artificial flavours, colours, and preservatives. The consumption of UPF in
the modern diet has increased dramaticall additives, such as artificial flavours, colours, and preservatives. The consumption of UPF in

the modern diet has increased dramatically in recent years, and this has raised concerns about

their potential impact on healt the modern diet has increased dramatically in recent years, and this has raised concerns about
their potential impact on health [7].
There is limited scientific evidence directly linking the consumption of UPF to an increa their potential impact on health [7].

62 There is limited scientific evidence

63 risk of LC. However, there is a gro

64 may increase the risk of other type

65 recent (2023) systematic review an

66 higher proportion of There is limited scientific evidence directly linking the consumption of UPF to an increased

risk of LC. However, there is a growing body of research suggesting that a diet high in UPF

may increase the risk of other type risk of LC. However, there is a growing body of research suggesting that a diet high in UPF
may increase the risk of other types of cancer, as well as other chronic diseases [8-10]. A
recent (2023) systematic review and me may increase the risk of other types of cancer, as well as other chronic diseases [8-10]. A
recent (2023) systematic review and meta-analysis, which did not include LC, found that a
higher proportion of UPF intake increase recent (2023) systematic review and meta-analysis, which did not include LC, found that a
higher proportion of UPF intake increases the risk of overall cancer by 13%, breast cancer by
11%, colorectal cancer by 30% and panc higher proportion of UPF intake increases the risk of overall cancer by 13%, breast cancer by 11%, colorectal cancer by 30% and pancreatic cancer by 49% [11]. Consistent epidemiological findings from population-based studi 11%, colorectal cancer by 30% and pancreatic cancer by 49% [11]. Consistent

epidemiological findings from population-based studies (UK biobank, the European

Prospective Investigation into Cancer and Nutrition (EPIC) stud epidemiological findings from population-based studies (UK biobank, the European

Prospective Investigation into Cancer and Nutrition (EPIC) study, the French NutriNet-Sante

cohort and US-based cohorts) have reported a li Frospective Investigation into Cancer and Nutrition (EPIC) study, the French NutriNet-Sante

cohort and US-based cohorts) have reported a link between UPF consumption and overall

cancer, ovarian, colorectal, breast and pa %70 cohort and US-based cohorts) have reported a link between UPF consumption and overall

21 cancer, ovarian, colorectal, breast and pancreatic cancer [12-17]. Only two of these studies

22 evaluated the association of UP 71 cancer, ovarian, colorectal, breast and pancreatic cancer [12-17]. Only two of these studies

27 evaluated the association of UPF and LC. These two studies have investigated the association

27 between UPF and LC using %72 evaluated the association of UPF and LC. These two studies have investigated the association
between UPF and LC using UK biobank and EPIC study and shown no association. One
3 73 between UPF and LC using UK biobank and EPIC study and shown no association. One

It is made available under a CC-BY-NC-ND 4.0 International license.

study found that a diet high in UPF was associated with an increased risk of all types of

rancer, including LC. However, the study did not specifically examine the relationship

between ultra-processed food consumption an cancer, including LC. However, the study did not specifically examine the relationship
between ultra-processed food consumption and LC risk [18].
While the relationship between UPF consumption and LC risk is not yet fully between ultra-processed food consumption and LC risk [18].

77 While the relationship between UPF consumption and LC 1

78 there is some evidence to suggest that a diet high in ultra-proc

increased risk of LC [19-24]. Exa While the relationship between UPF consumption and LC risk is not yet fully understood,

there is some evidence to suggest that a diet high in ultra-processed foods may be linked to an

increased risk of LC [19-24]. Examin there is some evidence to suggest that a diet high in ultra-processed foods may be linked to an
increased risk of LC [19-24]. Examining the association and understanding the potential link
between UPF consumption and LC ri increased risk of LC [19-24]. Examining the association and understanding the potential link

80 between UPF consumption and LC risk is important for developing effective strategies to

81 prevent this disease. Hence, the between UPF consumption and LC risk is important for developing effective strategies to

81 prevent this disease. Hence, the current study was aimed to investigate the association

82 between proportion of UPF intake and L

expect this disease. Hence, the current study was aimed to investigate the association
B2 between proportion of UPF intake and LC among older adults in United States of America
(USA).
E44 Methods
E44 Study Population a between proportion of UPF intake and LC among older adults in United States of America

83 (USA).

84 **Methods**

85 **Study Population and Study Design**

86 The study used data from the Prostate, Lung, Ovarian and Colorecta 83 (USA).
84 **Method**
85 **Study I**
86 The student
86 The student
87 cancer s
88 whether
89 approxi
90 (screeni
91 aged be 84 **Methods**
85 **Study Po**
86 The study
87 cancer scr
88 whether
89 approxima
90 (screening
91 aged betw
92 cancer, v **Study Population and Study Design**

86 The study used data from the Prostate

87 cancer screening trial in 10 study cent

88 whether screening examinations r

89 approximately 155,000 older adults to

90 (screening examin The study used data from the Prostate, Lung, Ovarian and Colorectal Cancer trial (PLCO), a
cancer screening trial in 10 study centers across the USA. The trial was designed to evaluate
whether screening examinations reduce cancer screening trial in 10 study centers across the USA. The trial was designed to evaluate
whether screening examinations reduces cancer mortality by randomly allocating
approximately 155,000 older adults to the control whether screening examinations reduces cancer mortality by randomly allocating
approximately 155,000 older adults to the control arm (usual care) or to the intervention arm
(screening examination). The randomization began approximately 155,000 older adults to the control arm (usual care) or to the intervention arm

90 (screening examination). The randomization began in 1993. Eligible study subjects were

91 aged between 55 to 74 years at en 90 (screening examination). The randomization began in 1993. Eligible study subjects were
91 aged between 55 to 74 years at enrolment and free from prostate, lung, colorectal and ovarian
92 ancer, with additional criteria 91 aged between 55 to 74 years at enrolment and free from prostate, lung, colorectal and ovarian

92 cancer, with additional criteria documented elsewhere [25]. Initial information on

93 demographic, lifestyle, medical hi exametry with additional criteria documented elsewhere [25]. Initial information on
demographic, lifestyle, medical history, family history and medication used was collected
through the baseline questionnaire (BQ). The die demographic, lifestyle, medical history, family history and medication used was collected
through the baseline questionnaire (BQ). The dietary history questionnaire (DHQ) was
administered to both arms commencing in 1998 an 94 through the baseline questionnaire (BQ). The dietary history questionnaire (DHQ) was
95 administered to both arms commencing in 1998 and a total of 113,000 (77%) participants
96 provided a complete response with a 3-yea 95 administered to both arms commencing in 1998 and a total of 113,000 (77%) participants
96 provided a complete response with a 3-year median time to the study. Study subjects were
97 monitored approximately for 12 years 96 provided a complete response with a 3-year median time to the study. Study subjects were
97 monitored approximately for 12 years to obtain data related to the diagnosis of LC.
97 97 monitored approximately for 12 years to obtain data related to the diagnosis of LC.

It is made available under a CC-BY-NC-ND 4.0 International license.

Overall, 101,732 participants were eligible for dietary history and LC analysis (53,155 study
participants were excluded due to invalid BQ and DHQ). After examining the distribution of
total energy, we further excluded 5,1 participants were excluded due to invalid BQ and DHQ). After examining the distribution of
total energy, we further excluded 5,125 participants who were in the bottom and top 1% of
energy intakes, with 96,607 participants 100 total energy, we further excluded 5,125 participants who were in the bottom and top 1% of

101 energy intakes, with 96,607 participants remaining in the final analysis (**Supplementary Fig**

102 1). Ethics approval for 101 energy intakes, with 96,607 participants remaining in the final analysis (**Supplementary Fig**

102 1). Ethics approval for the trial was obtained from the US National Cancer Institute (NCI)

103 Review Boards and writt 102 1). Ethics approval for the trial was obtained from the US National Cancer Institute (NCI)
103 Review Boards and written informed consent was obtained from each participant. The data
104 for dietary history and lung ca

Review Boards and written informed consent was obtained from each participant. The data

104 for dietary history and lung cancer analysis were obtained using the Cancer Data Access

105 System (CDAS) after obtaining approv 104 for dietary history and lung cancer analysis were obtained using the Cancer Data Access
105 System (CDAS) after obtaining approval from NCI (project registration: PLCO-982).
106 **Data Collection and UPF Assessment**
107 105 System (CDAS) after obtaining approval from NCI (project registration: PLCO-982).

106 **Data Collection and UPF Assessment**

107 Baseline data on demographic characteristics (age, sex, race, marital status, ed

108 occ **Data Collection and UPF Assessment**

107 Baseline data on demographic charac

108 occupation, family income and study ar

109 self-reported medical history, personal

110 body-mass index (BMI)), family history

111 dietar Baseline data on demographic characteristics (age, sex, race, marital status, education, occupation, family income and study arm), types and date of diagnosis for cancer, treatment, self-reported medical history, personal occupation, family income and study arm), types and date of diagnosis for cancer, treatment,
self-reported medical history, personal lifestyle features (smoking, alcohol drinking, and
body-mass index (BMI)), family history self-reported medical history, personal lifestyle features (smoking, alcohol drinking, and

body-mass index (BMI)), family history of lung cancer, medication use, physical activity and

dietary habits were obtained from th 110 body-mass index (BMI)), family history of lung cancer, medication use, physical activity and
111 dietary habits were obtained from the BQ, DHQ, supplementary questionnaire (SQ) and brief
112 survey questionnaire (BSQ). dietary habits were obtained from the BQ, DHQ, supplementary questionnaire (SQ) and brief
survey questionnaire (BSQ). Dietary data were collected using a self-administered food
frequency questionnaire (FFQ), a validated as 112 survey questionnaire (BSQ). Dietary data were collected using a self-administered food
113 frequency questionnaire (FFQ), a validated assessment tool which provides better nutrient
114 estimate[26]. All food items in t frequency questionnaire (FFQ), a validated assessment tool which provides better nutrient
estimate[26]. All food items in the DHQ were grouped into one of four categories from the
NOVA classification, with an emphasis on U

estimate[26]. All food items in the DHQ were grouped into one of four categories from the

NOVA classification, with an emphasis on UPF as described previously by Monteiro [27]. In

case of uncertainty regarding which cate 115 NOVA classification, with an emphasis on UPF as described previously by Monteiro [27]. In
116 case of uncertainty regarding which category the food or beverage belongs to, consensus was
117 reached among the researcher case of uncertainty regarding which category the food or beverage belongs to, consensus was
reached among the researchers (**Supplementary Table 1**).
From a total of 275 foods or beverages, 145 were categorized as UPF. UPF reached among the researchers (**Supplementary Table 1**).

118 From a total of 275 foods or beverages, 145 were catege

119 includes carbonated drinks, savory packaged snacks; ice

120 breads and buns; margarines and spread 118 From a total of 275 foods or beverages, 145 were categorized as UPF. UPF in this study
119 includes carbonated drinks, savory packaged snacks; ice cream, chocolate, confectionery;
120 breads and buns; margarines and sp 119 includes carbonated drinks, savory packaged snacks; ice cream, chocolate, confectionery;

120 breads and buns; margarines and spreads; cookies, pastries, and cakes; breakfast cereals,

121 cereal and energy bars; flavo 120 breads and buns; margarines and spreads; cookies, pastries, and cakes; breakfast cereals, cereal and energy bars; flavoured milk drinks; cocoa drinks; sweet desserts made from fruit with added sugars, artificial flavou 121 cereal and energy bars; flavoured milk drinks; cocoa drinks; sweet desserts made from fruit
122 with added sugars, artificial flavours and texturizing agents; cooked seasoned vegetables with
5 122 with added sugars, artificial flavours and texturizing agents; cooked seasoned vegetables with

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

ready-made sauces; meat and chicken extracts and instant sauces; health and slimming
products such as powdered or fortified meal and dish substitutes; ready to heat products;
poultry and fish nuggets and sticks, sausages, products such as powdered or fortified meal and dish substitutes; ready to heat products;
poultry and fish nuggets and sticks, sausages, burgers, cold cuts, hot dogs, and other
reconstituted meat products, and instant soup 125 poultry and fish nuggets and sticks, sausages, burgers, cold cuts, hot dogs, and other
126 reconstituted meat products, and instant soups, and noodles. These food items were further
127 regrouped into sugary drinks; pr

reconstituted meat products, and instant soups, and noodles. These food items were further
regrouped into sugary drinks; processed meats; milk dessert, yogurt, and soy products;
cookies, pies, and pastries; margarine and d regrouped into sugary drinks; processed meats; milk dessert, yogurt, and soy products;
cookies, pies, and pastries; margarine and dressings; sweets and other condiments; salty
smacks; quick bread; and others (**Supplementar** cookies, pies, and pastries; margarine and dressings; sweets and other condiments; salty
snacks; quick bread; and others (**Supplementary Table 1**).
130 UPF was measured by calculating the weight ratio of all food items cla snacks; quick bread; and others (**Supplementary Table 1**).
130 UPF was measured by calculating the weight ratio of all fo
131 total weight of all food items consumed by individuals per
132 ratio was chosen instead of an en 130 UPF was measured by calculating the weight ratio of all food items classified as UPF to the

131 total weight of all food items consumed by individuals per day (% grams/day). This weight

132 ratio was chosen instead o 131 total weight of all food items consumed by individuals per day (% grams/day). This weight

132 ratio was chosen instead of an energy ratio because it considers UPF with no or low-calorie

133 content, such as artificia 132 ratio was chosen instead of an energy ratio because it considers UPF with no or low-calorie

133 content, such as artificially sweetened beverages, as well as non-nutritional factors associated

134 with food processin 133 content, such as artificially sweetened beverages, as well as non-nutritional factors associated
134 with food processing (such as neoformed contaminants, additives, and alterations to the
135 structure of raw foods)[1 with food processing (such as neoformed contaminants, additives, and alterations to the
structure of raw foods)[12, 13, 28]. Additionally, the caloric contribution of UPF was
determined by calculating the fraction of energ

135 structure of raw foods)[12, 13, 28]. Additionally, the caloric contribution of UPF was
136 determined by calculating the fraction of energy from UPF to the total energy from all food
137 items consumed per day.
138 **Ou** determined by calculating the fraction of energy from UPF to the total energy from all food

items consumed per day.
 138 Outcome Assessment

The outcome of this study was incidence of LC. LC diagnosis was made by selfitems consumed per day.

138 **Outcome Assessment**

139 The outcome of this student

140 responses from partici

141 documented from abnorm

142 confirmed from medical

143 International Classificatie

144 includes either n **Outcome Assessment**
139 The outcome of this s
140 responses from parti
141 documented from abno
142 confirmed from medic
143 International Classifica
144 includes either non-sn
145 (SCLC) (n=242). Lung
146 and was exclude 139 The outcome of this study was incidence of LC. LC diagnosis was made by self-reported

140 responses from participants through annual follow-up questionnaires. Cases were

141 documented from abnormal x-ray results, d 140 responses from participants through annual follow-up questionnaires. Cases were
141 documented from abnormal x-ray results, death certificates and relative reports. LC diagnosis
142 confirmed from medical record abstr documented from abnormal x-ray results, death certificates and relative reports. LC diagnosis

confirmed from medical record abstraction as per histopathologic type derived from the

International Classification of Diseas 142 confirmed from medical record abstraction as per histopathologic type derived from the

143 International Classification of Diseases-Oncology, 2^{nd} edition (ICD-O-2) morphology that

144 includes either non-small ce International Classification of Diseases-Oncology, $2nd$ edition (ICD-O-2) morphology that 143 International Classification of Diseases-Oncology, 2^{nd} edition (ICD-O-2) morphology that

144 includes either non-small cell lung cancer (NSCLC) (n=1,464) or small cell lung cancer

145 (SCLC) (n=242). Lung carcino 144 includes either non-small cell lung cancer (NSCLC) (n=1,464) or small cell lung cancer

145 (SCLC) (n=242). Lung carcinoid tumour was not considered confirmed LC during the trial

146 and was excluded in this analysis. 145 (SCLC) (n=242). Lung carcinoid tumour was not considered confirmed LC during the trial
146 and was excluded in this analysis.
147 **Statistical Analysis** 6 146 and was excluded in this analysis.
147 **Statistical Analysis**

147 **Statistical Analysis**

It is made available under a CC-BY-NC-ND 4.0 International license.

We utilized an inverse probability of censoring weighting (IPCW) estimator to reduce bias

caused by censoring, specifically dependent censoring [29, 30]. This method has been

employed in right-truncated data [31] and can caused by censoring, specifically dependent censoring [29, 30]. This method has been

employed in right-truncated data [31] and can address the issue of censored subjects by

assigning greater weight to subjects with simil

employed in right-truncated data [31] and can address the issue of censored subjects by
assigning greater weight to subjects with similar characteristics who are not censored [32].
By making the positivity assumption, this 151 assigning greater weight to subjects with similar characteristics who are not censored [32].

152 By making the positivity assumption, this approach enables us to consistently estimate the

165 effects of covariates an 152 By making the positivity assumption, this approach enables us to consistently estimate the effects of covariates and avoids the need to estimate baseline hazards [31].

154 We applied Cox regression models with IPCW to 153 effects of covariates and avoids the need to estimate baseline hazards [31].
154 We applied Cox regression models with IPCW to estimate the hazard ra
155 confidence interval (CI) for the association between proportion We applied Cox regression models with IPCW to estimate the hazard ratio (HR) and 95%
confidence interval (CI) for the association between proportion of UPF consumption and LC
risk. The follow-up time was defined as the tim confidence interval (CI) for the association between proportion of UPF consumption and LC

156 risk. The follow-up time was defined as the time between completion of DHQ and date of

167 diagnosis of LC, death, drop-out, o 156 risk. The follow-up time was defined as the time between completion of DHQ and date of diagnosis of LC, death, drop-out, or the end of the study up to 31 December 2009. We built five models in incremental steps by adju diagnosis of LC, death, drop-out, or the end of the study up to 31 December 2009. We built
five models in incremental steps by adjusting for potential confounders, selected from
literature and prior knowledge [12, 13, 28, 158 five models in incremental steps by adjusting for potential confounders, selected from

159 literature and prior knowledge [12, 13, 28, 33]. These covariates considered for the model

26 adjustment were age (continuou 159 literature and prior knowledge [12, 13, 28, 33]. These covariates considered for the model

160 adjustment were age (continuous), sex (men, women), marital status (married, widowed,

161 divorced, separated/never marr adjustment were age (continuous), sex (men, women), marital status (married, widowed, divorced, separated/never married), education (up to grade 12 completion, post high school and some college, and under and postgraduate divorced, separated/never married), education (up to grade 12 completion, post high school
and some college, and under and postgraduate), ethnicity (Hispanic or non-Hispanic), study
arm (control, intervention), BMI (<18.5 262 and some college, and under and postgraduate), ethnicity (Hispanic or non-Hispanic), study

263 arm (control, intervention), BMI (<18.5, 18.5-24.99, 25-29.99, \geq 30+), cigarette smoking

264 status (never, current, 163 arm (control, intervention), BMI (<18.5, 18.5-24.99, 25-29.99, ≥30+), cigarette smoking

164 status (never, current, former), alcohol intake(g /day), total energy (kcal/day), aspirin use (yes,

165 no), history of ba 164 status (never, current, former), alcohol intake(g/day), total energy (kcal/day), aspirin use (yes,

165 no), history of baseline comorbidity (yes, no), and family history of LC (yes, no). Models

166 were also adjuste 165 no), history of baseline comorbidity (yes, no), and family history of LC (yes, no). Models

166 were also adjusted for average family income (<\$50,000, \$50,000-\$99,000 and \geq \$100,000)

167 and physical activity me 166 were also adjusted for average family income (<\$50,000, \$50,000-\$99,000 and ≥ \$100,000) and physical activity measured in total time spent (in minutes) during each session doing moderate-to-strenuous exercise, as rec 167 and physical activity measured in total time spent (in minutes) during each session doing
168 moderate-to-strenuous exercise, as recorded in the self-reported SQ. Since cigarette smoking
169 is a well-established risk moderate-to-strenuous exercise, as recorded in the self-reported SQ. Since cigarette smoking
169 is a well-established risk factor for LC, we further refined the models by considering the
170 intensity and duration of smok 169 is a well-established risk factor for LC, we further refined the models by considering the
170 intensity and duration of smoking for both current and former smokers. Smokers were
171 classified into the following group 170 intensity and duration of smoking for both current and former smokers. Smokers were

171 classified into the following groups: never smokers, current smokers consuming 1-10

172 cigarettes per day, current smokers cons 171 classified into the following groups: never smokers, current smokers consuming 1-10 cigarettes per day, current smokers consuming 11-20 cigarettes per day, current smokers 172 cigarettes per day, current smokers consuming 11-20 cigarettes per day, current smokers

It is made available under a CC-BY-NC-ND 4.0 International license.

213 consuming 21 or more cigarettes per day, former smokers who quit within the past 10 years,

2174 former smokers who quit 11-20 years ago, and former smokers who quit more than 20 years

2175 ago [13, 34]. We also cons 174 former smokers who quit 11-20 years ago, and former smokers who quit more than 20 years

175 ago [13, 34]. We also consider cigar and pipe smoking in the analyses.

176 Cox regression with restricted cubic splines was ago [13, 34]. We also consider cigar and pipe smoking in the analyses.

Cox regression with restricted cubic splines was performed to exa

between per 10% increment in UPF intake and LC risk with three kno

selected based 176 Cox regression with restricted cubic splines was performed to examine the relationship
177 between per 10% increment in UPF intake and LC risk with three knots (10th, 50th, and 90th),
178 selected based on Akaike between per 10% increment in UPF intake and LC risk with three knots $(10^{th}, 50^{th},$ and $90^{th})$. between per 10% increment in UPF intake and LC risk with three knots (10^m, 50^m, and 90^m),
178 selected based on Akaike Information Criterion (AIC). In addition to using IPCW, we
179 conducted competing risk regressio

selected based on Akaike Information Criterion (AIC). In addition to using IPCW, we conducted competing risk regression analyses to consider the impact of deaths that occurred before the diagnosis of LC on the observed rel conducted competing risk regression analyses to consider the impact of deaths that occurred
1790 before the diagnosis of LC on the observed relationship between the quintile of UPF
1791 consumption and the risk of LC.
1792 180 before the diagnosis of LC on the observed relationship between the quintile of UPF
181 consumption and the risk of LC.
182 Subgroup analysis was carried out by stratifying the analysis by sex, age group, race,
183 cig consumption and the risk of LC.

182 Subgroup analysis was carried

183 cigarette smoking, BMI, family

184 bronchitis, and emphysema

185 multiplicative interactions of

186 differences.

187 Effect modification was asses Subgroup analysis was carried out by stratifying the analysis by sex, age group, race,

183 cigarette smoking, BMI, family history of LC, history of hypertension, diabetes, chronic

184 bronchitis, and emphysema to determi

istantic smoking, BMI, family history of LC, history of hypertension, diabetes, chronic
thronchitis, and emphysema to determine whether associations were modified by
multiplicative interactions of covariates and avoid pote 184 bronchitis, and emphysema to determine whether associations were modified by

185 multiplicative interactions of covariates and avoid potentially misleading subgroup

186 differences.

187 Effect modification was asses multiplicative interactions of covariates and avoid potentially misleading subgroup
186 differences.
187 Effect modification was assessed using Cox regression to determine the relative excess risk
188 due to interaction (R 186 differences.
187 Effect modi:
188 due to intera
189 and synerg:
190 confidence i
191 exposure and
192 and no diabe
193 Interactions
194 measures m 187 Effect modification was assessed using Cox regression to determine the relative excess risk
188 due to interaction (RERI: RR11–RR10–RR01+1), attributable proportion (AP: RERI/RR11),
189 and synergy index (SI: (RR11–1)/ 188 due to interaction (RERI: RR11–RR10–RR01+1), attributable proportion (AP: RERI/RR11),

189 and synergy index (SI: (RR11–1)/(RR10+RR01–1)) on an additive scale, with 95%

190 confidence intervals [35]. RR11 represents 189 and synergy index (SI: (RR11−1)/(RR10+RR01−1)) on an additive scale, with 95%

190 confidence intervals [35]. RR11 represents the relative risk (RR) in the groups with high UPF

191 exposure and diabetes exposure, RR1 190 confidence intervals [35]. RR11 represents the relative risk (RR) in the groups with high UPF exposure and diabetes exposure, RR10 represents the RR in the groups with high UPF intake

201 and no diabetes, and RR01 re 191 exposure and diabetes exposure, RR10 represents the RR in the groups with high UPF intake

192 and no diabetes, and RR01 represents the RR in the groups with low UPF intake and diabetes.

193 Interactions between UPF 2022 and no diabetes, and RR01 represents the RR in the groups with low UPF intake and diabetes.

2013 Interactions between UPF consumption and diabetes status were analysed using the surrogate

2014 measures mentioned ear 193 Interactions between UPF consumption and diabetes status were analysed using the surrogate

194 measures mentioned earlier. A value of zero for RERI and AP indicates no additive

195 interaction. A positive value sugge 194 measures mentioned earlier. A value of zero for RERI and AP indicates no additive

195 interaction. A positive value suggests a super-additive interaction, while a negative value

196 indicates a sub-additive interact 195 interaction. A positive value suggests a super-additive interaction, while a negative value

196 indicates a sub-additive interaction [36, 37]. A value of 1 for SI implies no interaction or

197 exactly additivity; SI 196 indicates a sub-additive interaction [36, 37]. A value of 1 for SI implies no interaction or exactly additivity; $SI > 1$ indicates positive interaction or more than additivity; $SI < 1$
8 197 exactly additivity; $SI > 1$ indicates positive interaction or more than additivity; $SI < 1$
8

It is made available under a CC-BY-NC-ND 4.0 International license.

198 suggests negative interaction or less than additivity [37]. The study also examined the
199 interaction between diabetes status (yes/no) and the quintile of UPF exposure to compare the
100 outcomes of both types of exp 199 interaction between diabetes status (yes/no) and the quintile of UPF exposure to compare the

200 outcomes of both types of exposure.

201 In Cox models, deviations from additivity can be assessed using the surrogate 200 outcomes of both types of exposure.

201 In Cox models, deviations from add

202 additive interaction obtained from

203 these measures may sometimes be co

204 use additive hazard models, which d

205 from additivity 201 In Cox models, deviations from additivity can be assessed using the surrogate measures of additive interaction obtained from the multiplicative models mentioned above. However, these measures may sometimes be counteradditive interaction obtained from the multiplicative models mentioned above. However,

202 these measures may sometimes be counter-intuitive and invalid. An alternative approach is to

204 use additive hazard models, whi 203 these measures may sometimes be counter-intuitive and invalid. An alternative approach is to use additive hazard models, which directly estimates the absolute magnitude of the deviation from additivity [38, 39]. There 204 use additive hazard models, which directly estimates the absolute magnitude of the deviation

205 from additivity [38, 39]. Therefore, we used additive hazard models to estimate the number

206 of additional lung canc 205 from additivity [38, 39]. Therefore, we used additive hazard models to estimate the number

206 of additional lung cancer incidents per 100,000 person-years of observation. We considered

207 the quintiles or binary c 206 of additional lung cancer incidents per 100,000 person-years of observation. We considered

207 the quintiles or binary categories of UPF intake (low, below the mean $(\leq 31.2\%)$, and high, \geq

208 the mean $(\geq 31$ 207 the quintiles or binary categories of UPF intake (low, below the mean $(\leq 31.2\%)$, and high, ≥ the mean $(\geq 31.2\%)$), diabetes status, and their interaction using the R package "timereg" [38].

209 Finally, to chec 208 the mean (≥31.2%)), diabetes status, and their interaction using the R package "timereg" [38].

209 Finally, to check the stability of the findings, we performed the following sensitivity

210 analyses: a) multiple im Finally, to check the stability of the findings, we performed the following sensitivity

210 analyses: a) multiple imputation for covariates with missing values including physical

211 activity (23,002; 24%) and family in analyses: a) multiple imputation for covariates with missing values including physical
211 activity (23,002; 24%) and family income (26,629; 28%); b) excluding participants with
212 history of hypertension, diabetes, chron 211 activity (23,002; 24%) and family income (26,629; 28%); b) excluding participants with

212 bistory of hypertension, diabetes, chronic bronchitis, emphysema and obese at baseline; c)

213 excluding LC cases that occurr 212 history of hypertension, diabetes, chronic bronchitis, emphysema and obese at baseline; c) excluding LC cases that occurred during the first five years of follow-up; d) Adjusting for processed meat, artificial sweeteni excluding LC cases that occurred during the first five years of follow-up; d) Adjusting for processed meat, artificial sweetening beverages, fruits and vegetables, fish consumption and nutrients such as fibers, omega-3, to 214 processed meat, artificial sweetening beverages, fruits and vegetables, fish consumption and
215 nutrients such as fibers, omega-3, total fat, protein, carbohydrates, and sodium; e)comparing
216 the findings with the p 215 nutrients such as fibers, omega-3, total fat, protein, carbohydrates, and sodium; e)comparing

216 the findings with the proportion of UPF (%kcal) of the total energy; g) considering

217 histopathological subtypes of 216 the findings with the proportion of UPF (%kcal) of the total energy; g) considering
217 histopathological subtypes of LC (NSCLC and SCLC) and h) removing putative confounders
218 (smoking, alcohol intake, and BMI) of l 217 histopathological subtypes of LC (NSCLC and SCLC) and h) removing putative confounders

218 (smoking, alcohol intake, and BMI) of lung cancer in the final model to see their impact on

219 the observed association betw 218 (smoking, alcohol intake, and BMI) of lung cancer in the final model to see their impact on

219 the observed association between UPF intake and LC risk. All statistical analyses were

220 performed using R-software ve 219 the observed association between UPF intake and LC risk. All statistical analyses were
220 performed using R-software version 4.2.3 and Stata version 18 (College Station, TX, USA).
221 **Results**
222 **Baseline Character** 220 performed using R-software version 4.2.3 and Stata version 18 (College Station, TX, USA).
221 **Results**
222 **Baseline Characteristics of Study Participants**
9

221 **Results** 222 **Baseline Characteristics of Study Participants**

It is made available under a CC-BY-NC-ND 4.0 International license.

223 Among the total participants, 50,803(52.6%) were female and the mean (SD) age was

224 65.58(5.74) years at baseline for all participants. The proportion of women was consistently

225 lower across the quintiles UPF co 224 65.58(5.74) years at baseline for all participants. The proportion of women was consistently

225 lower across the quintiles UPF consumption from 66.5% to 43.5% compared to men. A

226 slightly higher pattern of UPF co 225 lower across the quintiles UPF consumption from 66.5% to 43.5% compared to men. A
226 slightly higher pattern of UPF consumption was observed in younger adults (mean age of
227 64.6 vs 66 years). In addition, compared 226 slightly higher pattern of UPF consumption was observed in younger adults (mean age of 64.6 vs 66 years). In addition, compared to participants in the first quintile of UPF consumption, the number of participants in th 227 64.6 vs 66 years). In addition, compared to participants in the first quintile of UPF

228 consumption, the number of participants in the fifth quintile was higher among those

229 classified as obese (18.1% vs 27.8%),

228 consumption, the number of participants in the fifth quintile was higher among those

229 classified as obese (18.1% vs 27.8%), current cigarette smokers (6.3% vs 12.8%), current

230 alcohol drinkers (13.3% vs 18.7%) classified as obese (18.1% vs 27.8%), current cigarette smokers (6.3% vs 12.8%), current
alcohol drinkers (13.3% vs 18.7%), history of diabetes (6.2% vs 7.8%), and hypertensive
231 (30.1% vs 34.6 (**Table 1**).
232 The aver alcohol drinkers (13.3% vs 18.7%), history of diabetes (6.2% vs 7.8%), and hypertensive

231 (30.1% vs 34.6 (**Table 1**).

232 The average (SD) proportion of UPF consumption in the total diet (gm/day) was 31.2%

233 (14.0%) 231 (30.1% vs 34.6 (**Table 1**).

232 The average (SD) propor

233 (14.0%) (**Supplementary**

234 37.13% (**Supplementary**

235 contributed higher proport

236 proportion of UPF contrib

237 The predominant UPF gro

238 desse 232 The average (SD) proportion of UPF consumption in the total diet (gm/day) was 31.2% (14.0%) (**Supplementary Fig 2**) and the mean percentage of UPF consumption (%kcal) was 37.13% (**Supplementary Fig 3**). Sugary drinks, 233 (14.0%) (**Supplementary Fig 2**) and the mean percentage of UPF consumption (%kcal) was
234 37.13% (**Supplementary Fig 3**). Sugary drinks, milk dessert and processed meats
235 contributed higher proportion to the total 234 37.13% (**Supplementary Fig 3**). Sugary drinks, milk dessert and processed meats
235 contributed higher proportion to the total diet in the study participants (**Fig 1a**). The mean
236 proportion of UPF contribution was contributed higher proportion to the total diet in the study participants (**Fig 1a**). The mean
proportion of UPF contribution was relatively higher in men than women 33.45% vs 29.2%.
The predominant UPF groups consumed by proportion of UPF contribution was relatively higher in men than women 33.45% vs 29.2%.

237 The predominant UPF groups consumed by both men and women were sugary drinks, milk

238 dessert, yogurts, and soy products, proce

The predominant UPF groups consumed by both men and women were sugary drinks, milk

238 dessert, yogurts, and soy products, processed (white and red) meat, cakes, cookies, pies and

239 pastries, quick breads, and sugar, c 238 dessert, yogurts, and soy products, processed (white and red) meat, cakes, cookies, pies and

239 pastries, quick breads, and sugar, condiments, and sweets (Fig 1 b, c).

240 UPF Consumption and Lung Cancer Incidence
 pastries, quick breads, and sugar, condiments, and sweets (**Fig 1 b, c**).

240 **UPF Consumption and Lung Cancer Incidence**

241 A total of 1,596 incident cases of LC occurred during a median [IQR]

242 10.11) years and mea UPF Consumption and Lung Cancer Incidence

241 A total of 1,596 incident cases of LC occurred dur

242 10.11) years and mean (SD) follow-up time 8.8

243 person-years, the overall incidence rate of LC w.

244 cases per 10, 241 A total of 1,596 incident cases of LC occurred during a median [IQR] follow up of 9.4[8.02,

242 10.11) years and mean (SD) follow-up time 8.82(1.93) years. Over a total 853,968.16

243 person-years, the overall incide 242 10.11) years and mean (SD) follow-up time 8.82(1.93) years. Over a total 853,968.16
243 person-years, the overall incidence rate of LC was found to be 18.8 (95% CI: 17.7, 19.6)
244 cases per 10,000 individuals. The inc 243 person-years, the overall incidence rate of LC was found to be 18.8 (95% CI: 17.7, 19.6)

244 cases per 10,000 individuals. The incidence rate is higher in study subjects in the highest

245 quintile of UPF consumption 244 cases per 10,000 individuals. The incidence rate is higher in study subjects in the highest
245 quintile of UPF consumption compared to lowest (21 vs 18 per 10,000 observations)
246 (Supplementary Table 2).
210 245 quintile of UPF consumption compared to lowest (21 vs 18 per 10,000 observations)
246 (Supplementary Table 2).
10 246 (**Supplementary Table 2**).

It is made available under a CC-BY-NC-ND 4.0 International license.

247 Following adjustment for all covariates, the risk of LC incidence had no significant

248 association with a higher consumption of UPF (HR = 0.98; 95% CI: 0.83,1.15, p-for trend

249 = 0.92). Results from competing ri 248 association with a higher consumption of UPF (HR = 0.98; 95% CI: 0.83,1.15, p-for trend

249 = 0.32). Results from competing risk regression did not indicate significant association (HR =

250 0.95; 95% CI: 0.81,1.12)

249 =0.32). Results from competing risk regression did not indicate significant association (HR = 0.95; 95% CI: 0.81,1.12). Furthermore, restricted cubic spline analysis did not demonstrate a significant relationship betw 250 0.95; 95% CI: 0.81,1.12). Furthermore, restricted cubic spline analysis did not demonstrate a

251 significant relationship between UPF consumption and LC incidence (HR = 0.98; 95% CI:

252 0.85,1.13; p-nonlinear =0.4 251 significant relationship between UPF consumption and LC incidence (HR = 0.98; 95% CI:

252 0.85,1.13; p-nonlinear =0.44) (**Table 2, Fig 2**).

253 Subgroup analysis demonstrated that the magnitude of the observed assoc 252 0.85,1.13; p-nonlinear =0.44) (**Table 2, Fig 2**).

253 Subgroup analysis demonstrated that the magni

254 of LC and UPF consumption stratified by mo

255 0.05). However, when comparing the lowest

256 quintile among a 253 Subgroup analysis demonstrated that the magnitude of the observed association between risk

254 of LC and UPF consumption stratified by most covariates was unchanged (p-interaction >

255 0.05). However, when comparin 254 of LC and UPF consumption stratified by most covariates was unchanged (p-interaction > 0.05). However, when comparing the lowest quintile of UPF consumption to the highest quintile among adults with diabetes, those in

255 0.05). However, when comparing the lowest quintile of UPF consumption to the highest

256 quintile among adults with diabetes, those in the highest quintile had significantly higher risk

257 of LC (HR_{quintile5} v_s 256 quintile among adults with diabetes, those in the highest quintile had significantly higher risk

257 of LC (HR_{quintile5} v_s 1 = 2.44; 95%CI: 1.27, 4.67) compared to those without diabetes (HR_{quintile5} v_s 1 = 0 257 of LC (HR_{quintile5} vs 1= 2.44; 95%CI: 1.27, 4.67) compared to those without diabetes (HR_{quintile5} vs 1 = 0.92; 95% CI: 0.42, 2; P_{interaction} = 0.002) (**Fig 3**).

259 A further analysis was conducted to examine t 258 vs 1 = 0.92; 95% CI: 0.42, 2; P_{interaction} = 0.002) (**Fig 3**).

259 A further analysis was conducted to examine the relation

260 UPF and diabetes status in relation to the risk of LC

261 those with high UPF intake 259 A further analysis was conducted to examine the relationship between high and low intake of
260 UPF and diabetes status in relation to the risk of LC. Among individuals without diabetes,
261 those with high UPF intake 260 UPF and diabetes status in relation to the risk of LC. Among individuals without diabetes,

261 those with high UPF intake had a risk of LC of 0.99 (95% CI: 0.89, 1.10) compared to those

262 with low UPF intake. Howe 261 those with high UPF intake had a risk of LC of 0.99 (95% CI: 0.89, 1.10) compared to those

262 with low UPF intake. However, for individuals with both high UPF intake and diabetes, the

263 hazard ratio for the risk with low UPF intake. However, for individuals with both high UPF intake and diabetes, the

hazard ratio for the risk of LC was 1.17 (95% CI: 0.79, 1.75). There was evidence of a

positive interaction on the additive scale 263 hazard ratio for the risk of LC was 1.17 (95% CI: 0.79, 1.75). There was evidence of a

264 positive interaction on the additive scale (supra-additivity) with RERI = 0.13 (95% CI: -0.32,

265 0.58), AP = 0.10 (95% CI: 264 positive interaction on the additive scale (supra-additivity) with RERI = 0.13 (95% CI: -0.32, 0.58), AP = 0.10 (95% CI: -0.22, 0.42), and SI = 1.67 (95% CI: 0.22, 12.46). However, there was no statistically significa 265 0.58), AP = 0.10 (95% CI: -0.22, 0.42), and SI = 1.67 (95% CI: 0.22, 12.46). However, there was no statistically significant interaction between high UPF intake and diabetes on the multiplicative scale (p-value = 0.12 266 was no statistically significant interaction between high UPF intake and diabetes on the

267 multiplicative scale (p-value = 0.12). Nevertheless, a significant multiplicative interaction

268 was observed between qui 267 multiplicative scale (p-value = 0.12). Nevertheless, a significant multiplicative interaction
268 was observed between quintiles of UPF intake and diabetes (p-value = 0.007) (**Table 3**).
269 Using additive hazards reg was observed between quintiles of UPF intake and diabetes (p-value = 0.007) (**Table 3**).

269 Using additive hazards regression, it was estimated that 6 (95% CI: -13, 26) cases per

270 100,000 person-years of LC were attr Using additive hazards regression, it was estimated that 6 (95% CI: -13, 26) cases per 100,000 person-years of LC were attributable to high UPF consumption. For diabetes alone, 14 (95% CI: -50, 77) cases of LC were estimat 270 100,000 person-years of LC were attributable to high UPF consumption. For diabetes alone,
271 14 (95% CI: -50, 77) cases of LC were estimated. Due to the joint effect of high UPF intake
11 271 14 (95% CI: -50, 77) cases of LC were estimated. Due to the joint effect of high UPF intake
 11

It is made available under a CC-BY-NC-ND 4.0 International license.

272 and diabetes (both binary exposures), an additional 35 (95% CI: -50, 120) cases of LC were
273 estimated. Among participants with diabetes only, 186 (95% CI: 59, 313) cases per 100,000
274 person-years of LC were attri

estimated. Among participants with diabetes only, 186 (95% CI: 59, 313) cases per 100,000
person-years of LC were attributable to the highest quintile of UPF exposure. An additional
275 201 (95% CI: 70, 332) cases of LC we erson-years of LC were attributable to the highest quintile of UPF exposure. An additional

275 201 (95% CI: 70, 332) cases of LC were estimated due to the combined interaction between

276 the highest UPF intake and diabe 275 201 (95% CI: 70, 332) cases of LC were estimated due to the combined interaction between

276 the highest UPF intake and diabetes (**Table 4**).

277 Sensitivity analyses were undertaken by considering different scenario the highest UPF intake and diabetes (**Table 4**).
277 Sensitivity analyses were undertaken by consider
278 multiple imputation for observations with
279 unchanged (i.e., similar with the complete-cas
280 rule out reverse ca 277 Sensitivity analyses were undertaken by considering different scenarios. First, we undertook
278 multiple imputation for observations with missing values. The associations remained
279 unchanged (i.e., similar with th 278 multiple imputation for observations with missing values. The associations remained
279 unchanged (i.e., similar with the complete-cases results). The second scenario was used to
280 rule out reverse causation by excl 279 unchanged (i.e., similar with the complete-cases results). The second scenario was used to

280 rule out reverse causation by excluding participants with diseases at baseline such as

282 hypertension, diabetes, obesi 280 rule out reverse causation by excluding participants with diseases at baseline such as

281 hypertension, diabetes, obesity, and LC cases that occurred during the first five years of

282 follow-up. The results genera 281 hypertension, diabetes, obesity, and LC cases that occurred during the first five years of follow-up. The results generally unchanged but participants in the highest quintile of UPF intake compared to the lowest had a 282 follow-up. The results generally unchanged but participants in the highest quintile of UPF

283 intake compared to the lowest had a 5% of higher risk of LC incidence when LC cases

284 occurred in the first five years 283 intake compared to the lowest had a 5% of higher risk of LC incidence when LC cases

284 occurred in the first five years of follow-up were excluded (HR = 1.05; 95% CI: 0.83, 1.32;

285 p-trend = 0.047) (**Supplementar** 284 occurred in the first five years of follow-up were excluded (HR = 1.05; 95% CI: 0.83, 1.32;

285 p-trend = 0.047) (**Supplementary Table 3**). The association did not also differ by the

286 histopathological subtypes o 285 p-trend = 0.047) (**Supplementary Table 3**). The association did not also differ by the

286 histopathological subtypes of LC. However, a 10% increase in the UPF intake (in %

287 kcal/day) increased risk of LC by 32% 286 histopathological subtypes of LC. However, a 10% increase in the UPF intake (in % kcal/day) increased risk of LC by 32% (HR = 1.32; 1.15,1.52), a linear dose-response relationship (p-nonlinear = 0.82) (**Supplementary** 287 kcal/day) increased risk of LC by 32% (HR = 1.32; 1.15,1.52), a linear dose-response

288 relationship (p-nonlinear = 0.82) (**Supplementary Table 3, Supplementary Fig 4**).

289 Furthermore, when adjusted for artificia relationship (p-nonlinear = 0.82) (**Supplementary Table 3, Supplementary Fig 4**).

289 Furthermore, when adjusted for artificial sweetening beverages, consumption of UPF was

290 significantly increased the risk of LC by 5 Eurthermore, when adjusted for artificial sweetening beverages, consumption of UPF was

290 significantly increased the risk of LC by 53% (HR =1.53; 95% CI: 1.26, 1.86; p-trend

291 =0.032). However, the risk of lung cance 290 significantly increased the risk of LC by 53% (HR =1.53; 95% CI: 1.26, 1.86; p-trend

201 =0.032). However, the risk of lung cancer was decreased by 2% among participants in the

202 highest quintile of UPF intake com 291 =0.032). However, the risk of lung cancer was decreased by 2% among participants in the

292 highest quintile of UPF intake compared to lowest when adjusted for dietary fiber intake (HR

293 = 0.98; 95% CI: 0.83, 1.15 292 highest quintile of UPF intake compared to lowest when adjusted for dietary fiber intake (HR $= 0.98; 95\%$ CI: 0.83, 1.15; p-trend =0.864) (**Supplementary Table 3**).
 Discussion

In this multi-center prospective st

293 = 0.98; 95% CI: 0.83, 1.15; p-trend =0.864) (**Supplementary Table 3**).
294 **Discussion**
295 In this multi-center prospective study, we investigated the association b
296 percentage weight (%g/day) and the risk of LC in 294 **Discussion**
295 In this mult
296 percentage 295 In this multi-center prospective study, we investigated the association between UPF intake in
296 percentage weight (%g/day) and the risk of LC incidence among adults participating in
22 296 percentage weight (%g/day) and the risk of LC incidence among adults participating in 12

It is made available under a CC-BY-NC-ND 4.0 International license.

PLCO trial in the US. The finding of this study did not demonstrate link between a higher

proportion of UPF in the total diet (%g/day) and risk of LC across all participants. However,

during subgroup analysis, the study proportion of UPF in the total diet (%g/day) and risk of LC across all participants. However,
during subgroup analysis, the study showed that the risk of LC was twice as high among
adults in the highest quintile of UPF int 299 during subgroup analysis, the study showed that the risk of LC was twice as high among
200 adults in the highest quintile of UPF intake compared to study participants without diabetes.
201 Further analysis using Cox pr adults in the highest quintile of UPF intake compared to study participants without diabetes.
301 Further analysis using Cox proportional model on additive scale showed the effect of
302 interaction between UPF and diabete 301 Further analysis using Cox proportional model on additive scale showed the effect of interaction between UPF and diabetes is, in fact super-additive (where both RERI and AP are found to be greater than zero and SI is g interaction between UPF and diabetes is, in fact super-additive (where both RERI and AP are

303 found to be greater than zero and SI is greater than one). Quantification of the public health

304 burden attributed to the 503 found to be greater than zero and SI is greater than one). Quantification of the public health
504 burden attributed to the interaction between quintiles of UPF consumption and diabetes
505 revealed a total of 201 addi 304 burden attributed to the interaction between quintiles of UPF consumption and diabetes
305 revealed a total of 201 additional incident LC cases per 100,000 person-years due to these
306 joint effects.
307 Additionally,

revealed a total of 201 additional incident LC cases per 100,000 person-years due to these
306 joint effects.
307 Additionally, the risk of LC was 21% higher in participants within the highest quintile of
308 UPF intake ac 306 joint effects.
307 Additionally,
308 UPF intake a
309 the lowest qu
310
311 A few studie
312 association b
313 association b
314 despite LC b 307 Additionally, the risk of LC was 21% higher in participants within the highest quintile of
308 UPF intake according to total energy (% kcal/day) consumption compared to participants in
310 the lowest quintile.
312 A fe 308 UPF intake according to total energy (% kcal/day) consumption compared to participants in
310
310 A few studies from EPIC, UK Biobank, and a meta-analysis have investigated a positive
312 association between UPF consum 309 the lowest quintile.
310
311 A few studies from
312 association betweer
313 association betweer
314 despite LC being t
315 cancer [40]. A r
315 statistically non-sig
317 UPF intake compa 311
312
313
313
314
315
316
317 311 A few studies from EPIC, UK Biobank, and a meta-analysis have investigated a positive
312 association between UPF consumption and overall cancer risk [11-13]. However, the
313 association between UPF consumption and th 312 association between UPF consumption and overall cancer risk [11-13]. However, the
313 association between UPF consumption and the risk of LC has not yet been well established,
314 despite LC being the second most commo 313 association between UPF consumption and the risk of LC has not yet been well established, despite LC being the second most commonly diagnosed cancer globally, following breast cancer [40]. A national representative stu 314 despite LC being the second most commonly diagnosed cancer globally, following breast
315 cancer [40]. A national representative study from the UK demonstrated a borderline
316 statistically non-significant higher risk 315 cancer [40]. A national representative study from the UK demonstrated a borderline statistically non-significant higher risk (25%) of LC among people at the highest level of UPF intake compared to lowest [12]. In contr 316 statistically non-significant higher risk (25%) of LC among people at the highest level of
317 UPF intake compared to lowest [12]. In contrast, a study from European countries, EPIC
318 study showed that there was a no 317 UPF intake compared to lowest [12]. In contrast, a study from European countries, EPIC
318 study showed that there was a non-significant inverse association between UPF consumption
319 and LC, with a 4% lower risk of L 318 study showed that there was a non-significant inverse association between UPF consumption
319 and LC, with a 4% lower risk of LC among subjects at the highest level of UPF consumption
320 [13]. 319 and LC, with a 4% lower risk of LC among subjects at the highest level of UPF consumption [13].
320 [13]. 320 [13].

321 The current study revealed a positive association between LC incidence and a higher
322 consumption of UPF (% gm/day) only among participants who had diabetes at baseline.
323 When UPF consumption was measured in terms 322 consumption of UPF (% gm/day) only among participants who had diabetes at baseline.
323 When UPF consumption was measured in terms of energy ratio (% kcal/day), the risk of LC
324 increased among participants with high When UPF consumption was measured in terms of energy ratio (% kcal/day), the risk of LC
increased among participants with highest level of UPF consumption.
325 The underlying mechanism for the observed association may be e 324 increased among participants with highest level of UPF consumption.
325 The underlying mechanism for the observed association may be exp
between hyperglycaemia and central obesity-cancer linkage, resulted
327 and insu The underlying mechanism for the observed association may be explained by the interplay
325 between hyperglycaemia and central obesity-cancer linkage, resulted from insulin-resistance
327 and insulin-like growth factor 1, between hyperglycaemia and central obesity-cancer linkage, resulted from insulin-resistance
and insulin-like growth factor 1, and adipokine pathophysiology and systemic inflammation
from circulating pro-inflammatory cytoki 327 and insulin-like growth factor 1, and adipokine pathophysiology and systemic inflammation
328 from circulating pro-inflammatory cytokines interleukin-6,8 and 1β, tumour necrosis factor-
329 a, vascular endothelial grow 328 from circulating pro-inflammatory cytokines interleukin-6,8 and 1β, tumour necrosis factor-
329 a, vascular endothelial growth factor, chemokine, ligand 2 and interferon [41-43]. A growing
330 body of evidence support a, vascular endothelial growth factor, chemokine, ligand 2 and interferon [41-43]. A growing
body of evidence supports the idea that abdominal obesity, which can be measured by waist
circumference or waist-to-hip ratio, a 330 body of evidence supports the idea that abdominal obesity, which can be measured by waist
331 circumference or waist-to-hip ratio, and metabolic dysregulation, such as hyperglycaemia,
332 insulin resistance, and dyslip 331 circumference or waist-to-hip ratio, and metabolic dysregulation, such as hyperglycaemia,
332 insulin resistance, and dyslipidaemia, may the underlying biological mechanisms that explain
333 the link between consumptio insulin resistance, and dyslipidaemia, may the underlying biological mechanisms that explain
the link between consumption of UPF and the risk of LC. National representative prospective
studies from Korea, the USA and the U

333 the link between consumption of UPF and the risk of LC. National representative prospective
334 studies from Korea, the USA and the UK have emphasized the significance of considering
335 metabolic status and markers wh studies from Korea, the USA and the UK have emphasized the significance of considering
335 metabolic status and markers when it comes to the primary prevention of lung cancer and the
336 identification of high-risk populat metabolic status and markers when it comes to the primary prevention of lung cancer and the

identification of high-risk populations for lung cancer screening [44-46].

The direct association of UPF consumption and risk of identification of high-risk populations for lung cancer screening [44-46].
337 The direct association of UPF consumption and risk of obesity, type 2 di
338 sufficiently well documented [8, 9, 47] and type 2 diabetes increa 337 The direct association of UPF consumption and risk of obesity, type 2 diabetes, and CVD are
338 sufficiently well documented [8, 9, 47] and type 2 diabetes increases the risk of LC [48-50].
339 Sudies showed that a 10 338 sufficiently well documented [8, 9, 47] and type 2 diabetes increases the risk of LC [48-50].
339 Studies showed that a 10 cm increase in waist circumference had 10% higher risk of LC [51,
340 S2]. Central adiposity af Studies showed that a 10 cm increase in waist circumference had 10% higher risk of LC [51, 52]. Central adiposity affects overall survival in LC and adiposity is inversely associated with inflammatory genes which may downr 52]. Central adiposity affects overall survival in LC and adiposity is inversely associated
341 with inflammatory genes which may downregulate the anti-tumour immune response[53, 54].
342 Metabolic effect of central obesit with inflammatory genes which may downregulate the anti-tumour immune response[53, 54].

342 Metabolic effect of central obesity encompasses deranged insulin signalling, increased steroid

343 hormone signalling, increased 342 Metabolic effect of central obesity encompasses deranged insulin signalling, increased steroid
343 hormone signalling, increased glucose utilization, fatty acid utilization and aberrant adipokine
344 signalling [55]. G 343 hormone signalling, increased glucose utilization, fatty acid utilization and aberrant adipokine
344 signalling [55]. Generally, dietary patterns with higher UPF proportion are nutritionally
345 inferior and high in en 344 signalling [55]. Generally, dietary patterns with higher UPF proportion are nutritionally
345 inferior and high in energy, fat, hydrogenated fat, free sugars, and low dietary fiber, that all
345 345 inferior and high in energy, fat, hydrogenated fat, free sugars, and low dietary fiber, that all

346 promote pro-inflammatory response, oxidative stress, metabolic dysregulation, and
347 carcinogenicity [27, 44, 45]. This study highlighted that the observed association may not be
348 affected by residual confounding, carcinogenicity [27, 44, 45]. This study highlighted that the observed association may not be
348 affected by residual confounding, mainly by a history of cigarette smoking status, intensity,
349 pipe, and cigar smoking. N

affected by residual confounding, mainly by a history of cigarette smoking status, intensity,

349 pipe, and cigar smoking. No significant subgroup difference was detected between UPF

350 intake and risk of lung cancer.
 949 pipe, and cigar smoking. No significant subgroup difference was detected between UPF

1950 intake and risk of lung cancer by smoking status, BMI, family history of lung cancer and

1951 subtypes of lung cancer.

1952 M intake and risk of lung cancer by smoking status, BMI, family history of lung cancer and
351 subtypes of lung cancer.
352 Moreover, during food processing alteration in food matrices contribute to degradation of
353 essent s151 subtypes of lung cancer.

352 Moreover, during food

353 essential nutrients invol

354 Though evidence remain

355 UPF intake may be imp

356 resistance, dyslipidaemis

357 factors, adipokines, myol

358 This study a 352 Moreover, during food processing alteration in food matrices contribute to degradation of essential nutrients involved in promoting health and change in microbiota [12, 21, 56].

354 Though evidence remains inconclusiv essential nutrients involved in promoting health and change in microbiota [12, 21, 56].

354 Though evidence remains inconclusive, the mechanism for lung carcinogenesis in relation to

355 UPF intake may be implicated due

Though evidence remains inconclusive, the mechanism for lung carcinogenesis in relation to
355 UPF intake may be implicated due to metabolic disorders such as hyperglycaemia, insulin-
356 resistance, dyslipidaemia, and inf UPF intake may be implicated due to metabolic disorders such as hyperglycaemia, insulin-
resistance, dyslipidaemia, and inflammation due to altered levels of insulin-like growth
factors, adipokines, myokines and sex hormon resistance, dyslipidaemia, and inflammation due to altered levels of insulin-like growth

factors, adipokines, myokines and sex hormones [57-59].

This study also determined whether the observed association between UPF int factors, adipokines, myokines and sex hormones [57-59].

358 This study also determined whether the observed association

369 and %kcal/day and the risk of LC is altered by certain con

360 smoking status, baseline comorbi This study also determined whether the observed association between UPF intake (in %g/day, and %kcal/day and the risk of LC is altered by certain confounders such as age, sex, details of smoking status, baseline comorbidit 359 and %kcal/day and the risk of LC is altered by certain confounders such as age, sex, details of
360 smoking status, baseline comorbidity, BMI, alcohol consumption, histological subtype,
361 follow-up length, dietary ri 560 smoking status, baseline comorbidity, BMI, alcohol consumption, histological subtype,
561 follow-up length, dietary risk factors such as fruits and vegetables, processed meat, artificial
562 sweetening beverages, fish, 1611 follow-up length, dietary risk factors such as fruits and vegetables, processed meat, artificial
1622 sweetening beverages, fish, fiber, sodium, total fats and other nutrients not largely changed.
164 The risk of LC w 562 sweetening beverages, fish, fiber, sodium, total fats and other nutrients not largely changed.

363 The risk of LC was higher among participants with NSCLC subtype and after excluding LC

364 cases developed during the The risk of LC was higher among participants with NSCLC subtype and after excluding LC
364 cases developed during the first five years of follow-up with level of UPF consumption
365 increases. Adjusting for dietary fiber r cases developed during the first five years of follow-up with level of UPF consumption
365 increases. Adjusting for dietary fiber reduced the risk of LC, non-statistically significant
366 while adjusting for artificial swe 365 increases. Adjusting for dietary fiber reduced the risk of LC, non-statistically significant
366 while adjusting for artificial sweetening beverages significantly increased the risk. The
367 association was not largely

while adjusting for artificial sweetening beverages significantly increased the risk. The
association was not largely changed for other covariates.
So Our finding using the weight contribution of UPF consumption showed no association was not largely changed for other covariates.
368 Our finding using the weight contribution of UPF c
369 association with the risk of LC across all study parti-
370 between caloric contribution and LC. This cou 368 Our finding using the weight contribution of UPF consumption showed no significant association with the risk of LC across all study participants, contrary to the association between caloric contribution and LC. This co 369 association with the risk of LC across all study participants, contrary to the association
370 between caloric contribution and LC. This could be due to fact that the energy contribution of
370 15 370 between caloric contribution and LC. This could be due to fact that the energy contribution of 15

371 UPF can directly impact metabolic regulations and inducing oxidative stress than the weight
372 contribution of UPF which comprises non-energy yielding constituents such as water, and
373 artificial sweeteners [13, 33, 373 contribution of UPF which comprises non-energy yielding constituents such as water, and
373 artificial sweeteners [13, 33, 44, 45]. A well-designed, longitudinal study with adequate
374 number of cases that incorporate attificial sweeteners [13, 33, 44, 45]. A well-designed, longitudinal study with adequate
374 number of cases that incorporate biomarkers for central obesity, oxidative stress,
375 inflammation, and additives and other non

274 number of cases that incorporate biomarkers for central obesity, oxidative stress,
375 inflammation, and additives and other non-nutritional factors, may help in reaching a
376 definitive conclusion and provide a great inflammation, and additives and other non-nutritional factors, may help in reaching a
definitive conclusion and provide a greater understanding of the biological mechanism(s)
underlying the UPF consumption and LC associati definitive conclusion and provide a greater understanding of the biological mechanism(s)
377 underlying the UPF consumption and LC association.
378 This study has important limitations. The NOVA grouping was performed usin underlying the UPF consumption and LC association.
378 This study has important limitations. The NOVA g
dietary data up to 25 years ago as a measure for usua
380 the market have been continuously changed and L
381 minimall 378 This study has important limitations. The NOVA grouping was performed using a single
379 dietary data up to 25 years ago as a measure for usual dietary exposure. Since then, foods in
380 the market have been continuous dietary data up to 25 years ago as a measure for usual dietary exposure. Since then, foods in
380 the market have been continuously changed and UPF has become more dominate than
381 minimally or unprocessed food groups in 380 the market have been continuously changed and UPF has become more dominate than
381 minimally or unprocessed food groups in the American food system. Thus, the caloric and
382 weight contribution of UPF may be underest minimally or unprocessed food groups in the American food system. Thus, the caloric and
weight contribution of UPF may be underestimated and could not represent the current UPF
consumption pattern in America. Recall bias f weight contribution of UPF may be underestimated and could not represent the current UPF
consumption pattern in America. Recall bias from dietary assessment and misclassification
bias from categorization of food items coul 383 consumption pattern in America. Recall bias from dietary assessment and misclassification
384 bias from categorization of food items could not be ruled out even if a validated FFQ and
385 NOVA food classification were 384 bias from categorization of food items could not be ruled out even if a validated FFQ and
385 NOVA food classification were used. The findings of the current study could only be inferred
386 for the general aged 55 yea NOVA food classification were used. The findings of the current study could only be inferred
385 for the general aged 55 years and over and the follow-up duration is relatively short (12
387 years). The study did not inves 386 for the general aged 55 years and over and the follow-up duration is relatively short (12 years). The study did not investigate potential biomarkers that may mediate the observed association between UPF and LC such as %387 years). The study did not investigate potential biomarkers that may mediate the observed
388 association between UPF and LC such as measures of body fat composition, inflammatory
389 factors and non-nutritional factor 388 association between UPF and LC such as measures of body fat composition, inflammatory
389 factors and non-nutritional factors associated with UPF consumption (additives, preservatives
390 and neoformed contaminants) an 389 factors and non-nutritional factors associated with UPF consumption (additives, preservatives
390 and neoformed contaminants) and potential confounding factors related to environmental or
391 occupational exposures.
39

390 and neoformed contaminants) and potential confounding factors related to environmental or
391 occupational exposures.
392 **Conclusions**
393 In summary, our findings showed that adults with diabetes and a higher consump 391 occupational exposures.
392 **Conclusions**
393 In summary, our finding
394 had a disproportionately
395 was positively associate 392 **Conclusions**
393 In summary,
394 had a disprop
395 was positivel 393 In summary, our findings showed that adults with diabetes and a higher consumption of UPF
394 had a disproportionately higher risk of LC. In addition, a higher caloric contribution of UPF
395 was positively associated 394 had a disproportionately higher risk of LC. In addition, a higher caloric contribution of UPF
395 was positively associated with a higher risk of LC among all study participants. Given the
 16 395 was positively associated with a higher risk of LC among all study participants. Given the

accumulating evidence relating to the adverse effect of UPF intake on overall cancer risk,

sonsideration of the degree of food processing and integrating public health policies that

promote healthy foods may be critical consideration of the degree of food processing and integrating public health policies that
398 promote healthy foods may be critical in reducing the modifiable burden of LC. Limiting a
399 higher level of UPF consumption a 398 promote healthy foods may be critical in reducing the modifiable burden of LC. Limiting a
399 higher level of UPF consumption and regulation of metabolic biomarkers could prevent a
310 higher number of LC cases. Additi

399 higher level of UPF consumption and regulation of metabolic biomarkers could prevent a

400 higher number of LC cases. Additionally, further research is needed to better understand the

401 relationship between UPF con implear number of LC cases. Additionally, further research is needed to better understand the

relationship between UPF consumption and the incidence of LC.
 Acknowledgements

TCM is grateful to thank for support provide relationship between UPF consumption and the incidence of LC.
 Acknowledgements

TCM is grateful to thank for support provided by the Austri

Training Program Scholarship. The authors thank the National C

NCI's data col Acknowledgements

403 TCM is grateful to

404 Training Program Sc

405 NCI's data collected l

406 Trial.

407 **Statement of author**

408 T.C.M: involved in

methodology, projec

410 the original draft, re

TCM is grateful to thank for support provided by the Australian Government Research
Training Program Scholarship. The authors thank the National Cancer Institute for access to
NCI's data collected by the Prostate, Lung, Co Training Program Scholarship. The authors thank the National Cancer Institute for access to

NCI's data collected by the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening

Trial.
 Statement of authors' contri MCI's data collected by the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening

1405 Trial.

1407 Statement of authors' contributions to manuscript.

1408 T.C.M: involved in conceptualization, data curation, fo 406 Trial.

407 **Stater**

408 T.C.M

409 metho

410 the or

411 conce_l

412 the fin

413 Data **Statement of authors' contributions to manuscript.**
T.C.M: involved in conceptualization, data cura
methodology, project administration, resources, soft
the original draft, review & editing of the manuscrip
conceptualizat T.C.M: involved in conceptualization, data curation, formal analysis, investigation,
methodology, project administration, resources, software, validation, visualization, writing
the original draft, review & editing of the methodology, project administration, resources, software, validation, visualization, writing
the original draft, review & editing of the manuscript. Y.A.M, Z.S and T.K.G involved in
conceptualization; methodology, supervis the original draft, review & editing of the manuscript. Y.A.M, Z.S and T.K.G involved in
conceptualization; methodology, supervision, validation, visualization, review and editing of
the final version of the manuscript. Al 111 conceptualization; methodology, supervision, validation, visualization, review and editing of

112 the final version of the manuscript. All authors have read and approved the final manuscript.

113 Data Sharing. The PL 412 the final version of the manuscript. All authors have read and approved the final manuscript.
413 Data Sharing. The PLCO trial data are available upon request to The National Cancer
414 Institute at <u>Access to PLCO Dat</u> 413 Data Sharing. The PLCO trial data are available upon request to The National Cancer

414 Institute at <u>Access to PLCO Data, Images, and Biospecimens - Learn - PLCO - The Cancer</u>

415 <u>Data Access System</u>.
 416 Funding 1414 Institute at <u>Access to PLCO Data, Images, and Biospecimens - Learn - PLCO - The Cancer</u>

1415 Data Access System.

1416 **Funding:** This research did not receive any specific grant from funding agencies in the

1417 p 415 **Data Access System**.
416 **Funding:** This resea
417 public, commercial, o
418 **References** Funding: This research did not receive any specific grant from funding agencies in the

public, commercial, or not-for-profit sectors.
 418
 References
 419
 References

quantity public, commercial, or not-for-profit sectors.

418
 References
 References 418 419 References

420 $1₁$

- Cancer Epidemiology, 2021. 5.

422 2. Ebrahimi, H., et al., *Global, regional, and national burden of respiratory tract cancers and*

423 associated risk factors from 1990 to 2019: a systematic analysis for the Global Burd 221 Cancer Epidemiology, 2021. 3.

422 2. Ebrahimi, H., et al., *Global, re*

423 associated risk factors from 1.

424 Disease Study 2019. The Lancer

425 3. Fitzmaurice, C., et al., *Global,*

426 Life Lost, Years Lived W associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of

424 Disease Study 2019. The Lancet Respiratory Medicine, 2021. 9(9): p. 1030-1049.

425 3. Fitzmaurice, C., et al., Global, Regiona
-
-
-

- Extended Right First Factors from 1990 to 1991.

424 Bisease Study 2019. The Lancet Respiratory Medicine, 2021. 9(9): p. 1030-1049.

425 3. Fitzmaurice, C., et al., *Global, Regional, and National Cancer Incidence, Mortali* 224 Disease Stady 2019. The Lancet Respiratory Medicine, 2021. 9(9): p. 1030-1049.

425 3. Fitzmaurice, C., et al., *Global, Regional, and Disability-Adjusted Life-Years for 29 Ca*

426 Life Lost, *Years Lived With Disabil* Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups,

427 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol,

428 2019. 5(12): p. 1749-1768.
 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol,

1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol,

1990 1990 1990 1991 1749-1768.

1999 11 Prev 228 2019. 5(12): p. 1749-1768.

229 4. Prevention, C.f.D.C.a. An Update on Cancer Deaths in the United States. Atlanta, GA: US

230 Department of Health and Human Services, Centers for Disease Control and Prevention,

231 2019. 5(12): p. 1749-1768.

429 4. Prevention, C.f.D.C.a. An U

430 Department of Health and

431 Division of Cancer

432 https://www.cdc.gov/cance

433 5. GBD 2015 Risk Factors (

434 assessment of 79 behavior

435 cluste
- 429 4. Prevention, C.f.D.C.a. An Update on Cancer Deaths in the United States. Atlanta, GA: US Division of Cancer Prevention and Control. 2022; Available from:

https://www.cdc.gov/cancer/dcpc/research/update-on-cancer-deaths/index.htm.

433 5. GBD 2015 Risk Factors Collaborators. Global, regional, and national comp 132 https://www.cdc.gov/cancer/dcpc/research/update-on-cancer-deaths/index.htm.

433 5. *GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk*

434 assessment of 79 behavioural, environmenta 433 5. *GBD 2015 Risk Factors Collaborators. Global, regional, and national comparent*
434 assessment of 79 behavioural, environmental and occupational, and metabolise
435 clusters of risks, 1990–2015: a systematic analysi 434 assessment of 79 behavioural, environmental and occupational, and metabolic risks or
435 clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study
436 2015. Lancet, 2016. **388**(10053):
- 235 clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study
2015. Lancet, 2016. 388(10053): p. 1659-1724.
237 6. Lv, D., et al., *Fish Intake, Dietary Polyunsaturated Fatty Acids, and Lun* 2015. Lancet, 2016. 388(10053): p. 1659-1724.

437 6. Lv, D., et al., *Fish Intake, Dietary Polyunsaturated Fatty Acids, and Lung Cancer: Systematic

438 Review and Dose-Response Meta-Analysis of 1.7 Million Men and Women.*
-
- 2015. Lancet, 2016. 388(10055): p. 1059-1724.

437 6. Lv, D., et al., *Fish Intake, Dietary Polyunsatura*

438 *Review and Dose-Response Meta-Analysis of*

440 7. Juul, F., et al., *Ultra-processed food consumptional*

441 438 Review and Dose-Response Meta-Analysis of 1.7 Million Men and Women. Nutr Cancer,
439 2022.74(6): p. 1976-1985.
440 7. Juul, F., et al., *Ultra-processed food consumption among US adults from 2001 to 2018.* Am J
441 Cl 2022. 74(6): p. 1976-1985.

440 7. Juul, F., et al., *Ultra-processed food consumption among US adults from 2001 to 2018.* Am J

2011 Nutr, 2022. 115(1): p. 211-221.

442 8. Suksatan, W., et al., *Ultra-Processed Food Cons* 2022. 74(6): p. 1976-1985.

440 7. Juul, F., et al., Ultra-proces

Clin Nutr, 2022. 115(1): p. 2

442 8. Suksatan, W., et al., Ult

5ystematic Review and D.

444 2021. 14(1). 441 Clin Nutr, 2022. 115(1): p. 211-221.
442 8. Suksatan, W., et al., *Ultra-Processed Food Consumption and Adult Mortality Risk: A*
443 *Systematic Review and Dose-Response Meta-Analysis of 207,291 Participants.* Nutrient 2442 8. Suksatan, W., et al., *Ultra-Proces*
443 *Systematic Review and Dose-Resp.*
444 2021.14(1). 443 Systematic Review and Dose-Response Meta-Analysis of 207,291 Participants. Nutrients,
2021.14(1).
18 $\begin{array}{l} \begin{array}{c} \hline \text{444} \end{array} \end{array}$ 2021. 14(1). $2021. 14(1).$

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2024.09.27.24314515;](https://doi.org/10.1101/2024.09.27.24314515) this version posted September 30, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

470 of the US population aged 6 years and older. PLOS ONE, 2020. 15(7): p. e0236738.

- 471 20.
-
- Science and Technology, 2016. **48**: p. 63-68.

473 21. Viennois, E., et al., *Dietary Emulsifier-Induced Low-Grade Inflammation Promotes Colon*

474 *Carcinogenesis.* Cancer Res, 2017. **77**(1): p. 27-40.

475 22. Clarke, R Science and Technology, 2016. 48: p. 63-66.

473 21. Viennois, E., et al., *Dietary Emulsifier-Indi*

474 *Carcinogenesis.* Cancer Res, 2017. **77**(1): p. 2

475 22. Clarke, R.E., et al., *Dietary Advanced Glyca*

476 *Dise*
- Carcinogenesis. Cancer Res, 2017. **77**(1): p. 27-40.

475 22. Clarke, R.E., et al., *Dietary Advanced Glycation End Products and Risk Factors for Chronic

476 Disease: A Systematic Review of Randomised Controlled Trials. N*
-
-
-
-
-
- Carcinogenesis. Cancer Res, 2017. *T*(1): p. 27-40.

475 22. Clarke, R.E., et al., *Dietary Advanced Glycation B*

23. *NTP (National Toxicology Program). Report on*

478 Triangle Park, *NC*: U.S. Department of Health ar
 Disease: A Systematic Review of Randomised Controlled Trials. Nutrients, 2016. 8(3): p. 125.

477 23. NTP (National Toxicology Program). Report on Carcinogens, Fifteenth Edition. Research

478 Triangle Park, NC: U.S. Depar Bisease: A systematic Review of Nandomised Controlled Trials: Natificity, 2010. 8(3): p. 125.

477 23. NTP (National Toxicology Program). Report on Carcinogens, Fifteenth Edition. Research

478 Triangle Park, NC: U.S. Depa Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service.

Attps://ntp.niehs.nih.gov/go/roc15 (EndNote XML) DOI: https://doi.org/10.22427/NTP-

<u>OTHER-1003</u>. 2021.

AB1 24. Banerjee, A., S. Mu https://ntp.niehs.nih.gov/go/roc15 (EndNote XML) DOI: https://doi.org/10.22427/NTP-

9THER-1003. 2021.

481 24. Banerjee, A., S. Mukherjee, and B.K. Maji, Worldwide flavor enhancer monosodium

9Iutamate combined with high <u>OTHER-1003</u>. 2021.
481 24. Banerjee, A., S. Mukherjee, and B.K. Maji, *Worldwide flavor enhancer monosodium*
482 glutamate combined with high lipid diet provokes metabolic alterations and systemic
483 anomalies: An overvi 481 24. Banerjee, A., S. N.
482 glutamate combine
483 anomalies: An overv
484 25. Prorok, P.C., et al.,
485 Screening Trial. Con
486 26. Subar, A.F., et al., C.
487 food frequency que:
488 154(12): p. 1089-99. 24. Banerjee, A., S. Mukherjee, A., S. Mukherjee, A., S. Mukherjee, and Systemic
2483 anomalies: An overview. Toxicol Rep, 2021. 8: p. 938-961.
25. Prorok, P.C., et al., *Design of the Prostate, Lung, Colorectal and Ovaria*
-
-
- 483

482 gournalies: An overview. Toxicol Rep, 2021. 8: p. 938-961.

484 25. Prorok, P.C., et al., *Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer*

485 *Screening Trial.* Control Clin Trials, 2000. 21(anomalies: An overview. Toxicol Rep, 2021. 8: p. 938-961.

484 25. Prorok, P.C., et al., *Design of the Prostate, Lung, Color*

485 *Screening Trial.* Control Clin Trials, 2000. **21**(6 Suppl): p. 27

486 26. Subar, A.F., e Screening Trial. Control Clin Trials, 2000. 21(6 Suppl): p. 273s-309s.

485 Screening Trial. Control Clin Trials, 2000. 21(6 Suppl): p. 273s-309s.

486 26. Subar, A.F., et al., *Comparative validation of the Block, Willett* Screening Trial. Control Clin Trials, 2000. 21(6 Supply). p. 273s-3053.

486 26. Subar, A.F., et al., *Comparative validation of the Block, Willett, and*

487 food frequency questionnaires : the Eating at America's Table S
-
-
- Food frequency questionnaires : the Eating at America's Table Study. Am J Epidemiol, 2001.

154(12): p. 1089-99.

164. Subar, A.F., et al., *Ultra-processed foods: what they are and how to identify them. Public*

1648 27. food frequency questionnaires : the Eating at America's Table Study. Am J Epidemiol, 2001.

488 154(12): p. 1089-99.

489 27. Monteiro, C.A., et al., *Ultra-processed foods: what they are and how to identify them.* Public
 488 27. Monteiro, C.A., et al.
489 27. Monteiro, C.A., et al.
491 28. Thibault, F., et al.,
492 *NutriNet-Santé prosp*
493 29. Robins, J.M. and D.M
494 *an AIDS Clinical Tria*
495 Biometrics, 2000. 56 490 Health Nutr, 2019. 22(5): p. 936-941.

491 28. Thibault, F., et al., Consumption of ultra-processed foods and cancer risk: results from

492 NutriNet-Santé prospective cohort. BMJ, 2018. 360: p. k322.

493 29. Robins, Freahr Nutr, 2015. 22(5): p. 936-941.

491 28. Thibault, F., et al., Consumption of

492 NutriNet-Santé prospective cohort. BN

493 29. Robins, J.M. and D.M. Finkelstein, Co

494 an AIDS Clinical Trial with inverse pr

Bio Added States and D.M. Finkelstein, Correcting for noncompliance and dependent censoring in

493 29. Robins, J.M. and D.M. Finkelstein, Correcting for noncompliance and dependent censoring in

494 495 2000.56(3): p. 779-88. warmer same prospective conort. BMJ, 2018. 360. p. k322.

493 29. Robins, J.M. and D.M. Finkelstein, Correcting for noncomplic

494 an AIDS Clinical Trial with inverse probability of censoring

495 Biometrics, 2000. 56(3): 494 an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests.
Biometrics, 2000. 56(3): p. 779-88.
20 495 Biometrics, 2000. 56(3): p. 779-88.
- $\frac{1}{200}$ Biometrics, 2000. $\frac{1}{20}$, p. 779-88.

- 496 30.
-

- deptying the inverse probability censoring weighted estimator. Stat Methods Med Res, 2018.

198. 27(2): p. 323-335.

199. 31. Vakulenko-Lagun, B., M. Mandel, and R.A. Betensky, Inverse probability weighting methods

199. T
-
-

- 27(2): p. 323-335.

499 31. Vakulenko-Lagun, B., M. Mandel, and R.A. Betensky, *Inverse probability weighting methods*

500 for Cox regression with right-truncated data. Biometrics, 2020. 76(2): p. 484-495.

501 32. Dong, 27(2): p. 323-335.

499 31. Vakulenko-Lagun,

500 *for Cox regression*

501 32. Dong, G., et al., i

502 statistic: an unbia.

503 2020. **30**(5): p. 882

504 33. Llavero-Valero, M.

505 *A prospective cohc*

506 34. Cordov 499 12. Analysis of the station of the station, parameters (2020, 76(2): p. 484-495.

499. Dong, G., et al., The inverse-probability of-censoring weighting (IPCW) adjusted win ratio

502 statistic: an unbiased estimator in
-
- 501 32. Dong, G., et al., *The inverse-probability-of-censoring weighting (IPCW) adjuste*
502 statistic: an unbiased estimator in the presence of independent censoring. J Biometrics, 2020. 30(5): p. 882-899.
503 2020. 30(5 502 statistic: an unbiased estimator in the presence of independent censoring. J Biopharm Stat,

503 2020. 30(5): p. 882-899.

504 33. Llavero-Valero, M., et al., *Ultra-processed foods and type-2 diabetes risk in the SUN* 2020. 30(5): p. 882-899.

504 33. Llavero-Valero, M., et al., *Ultra-processed foods and type-2 diabetes risk in the SUN project:*

4 *A prospective cohort study.* Clinical Nutrition, 2021. 40(5): p. 2817-2824.

506 34. Co 2020. 30(5): p. 882-899.

504 33. Llavero-Valero, M., et al.

505 *A prospective cohort stud*

506 34. Cordova, R., et al., *Const*

507 *and cardiometabolic dise*

508 p. 100771.

509 35. Rothman, K.J., S. Green

510 Kluw 4 *Soffride Condova, R., et al., Consumption of ultra-processed foods and risk of multimorbidity of cancer*

506 34. Cordova, R., et al., Consumption of ultra-processed foods and risk of multimorbidity of cancer

507 and c 506 34. Cordova, R., et al., *Consumption of ultra-processed foods and risk of multimational cohort study.* Lancet Reg F
505 2021. 40(5): p. 2017-2024.
509 31. Rothman, K.J., S. Greenland, and T.L. Lash, *Modern epidemiolo* 507 and cardiometabolic diseases: a multinational cohort study. Lancet Reg Health Eur, 2023. 35:

508 p. 100771.

509 35. Rothman, K.J., S. Greenland, and T.L. Lash, *Modern epidemiology*. Vol. 3. 2008: Wolters

511 36. Co
- 508 **and cardiometabone diseases: a multimational conort study. Eartet Reg Health Lei, 2023. 33.**
509 35. Rothman, K.J., S. Greenland, and T.L. Lash, *Modern epidemiology*. Vol. 3. 2008: Wolters
510 Kluwer Health/Lippincot 509 35. Rothman, 1
510 Kluwer Hea
511 36. Correia, K.
512 *Clustered-E*
513 37. Knol, M.J.,
514 *exposures.*
515 38. Rod, N.H., 6
516 Epidemiolo
-
- 510 Kluwer Health/Lippincott Williams & Wilkins Philadelphia.
511 36. Correia, K. and P.L. Williams, *Estimating the Relative Excess Risk Due to Interaction in*
512 *Clustered-Data Settings.* American Journal of Epidemiolo
-
-

 $2021. 71(3)$: p. 209-249.

- 511 36. Correia, K. and P.L. Williams, *Estimating the Relative L*
512 Clustered-Data Settings. American Journal of Epidemiology
513 37. Knol, M.J., et al., *Estimating measures of interaction or*
514 exposures. European J Clustered-Data Settings. American Journal of Epidemiology, 2018. 187(11): p. 2470-2480.

513 37. Knol, M.J., et al., *Estimating measures of interaction on an additive scale for preventive*

514 exposures. European Journal
- Ensieved Data Settings. American Journal of Epidemiology, 2010. 187(11): p. 2470-2480.

513 37. Knol, M.J., et al., *Estimating measures of interaction on an additive scale for preven.*

513 38. Rod, N.H., et al., *Additiv* exposures. European Journal of Epidemiology, 2011. 26(6): p. 433-438.

515 38. Rod, N.H., et al., *Additive Interaction in Survival Analysis: Use of the Additive Hazards Model.*

516 Epidemiology, 2012. 23(5).

517 39. Tur Exposures. European Journal of Epidemiology, 2011. 20(0): p. 433-438.

515 38. Rod, N.H., et al., *Additive Interaction in Survival Analysis: Use of the Ad*

516 Epidemiology, 2012. **23**(5).

517 39. Turner, M.C., et al., Epidemiology, 2012. 23(5).

515 Epidemiology, 2012. 23(5).

517 39. Turner, M.C., et al., *Interactions between cigarette smoking and ambient PM2.5 for*
 cardiovascular mortality. Environmental Research, 2017. 154: p. 30 Epidemiology, 2012. 23(3).

517 39. Turner, M.C., et al., *Inte*

518 *cardiovascular mortality*. Er

519 40. Sung, H., et al., *Global C*

520 *Mortality Worldwide for 3*

521 2021. **71**(3): p. 209-249. 518 cardiovascular mortality. Environmental Research, 2017. 154: p. 304-310.

519 40. Sung, H., et al., *Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and*

520 Mortality Worldwide for 36 Cancers in 185 Co Edialovascular mortality. Environmental Research, 2017. 154: p. 304-310.

519 40. Sung, H., et al., *Global Cancer Statistics 2020: GLOBOCAN Estimates*

520 Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer 520 *Mortality Worldwide for 36 Cancers in 185 Countries.* CA: A Cancer Journal for Clinicians,
321 2021. 71(3): p. 209-249.
21 521 2021. 71(3): p. 209-249.

It is made available under a CC-BY-NC-ND 4.0 International license.

- 522 41
-
-
-
-
- genotype. Int J Epidemiol, 2009. 38(4): p. 971-5.

524 42. Robado de Lope, L., et al., Tumour-adipose tissue crosstalk: fuelling tumour metastasis by

525 extracellular vesicles. Philos Trans R Soc Lond B Biol Sci, 2018. 3
- genotype. Int 3 Epidemiol, 2009. 38(4). p. 971-5.
524 42. Robado de Lope, L., et al., Tumour-adipose tiss
625 extracellular vesicles. Philos Trans R Soc Lond B E
626 43. Samet, J.M., Lung Cancer, Smoking, and Obe.
637 Nati extracellular vesicles. Philos Trans R Soc Lond B Biol Sci, 2018. 373(1737).

526 43. Samet, J.M., Lung Cancer, Smoking, and Obesity: It's Complicated. JNCI: Journal of the

527 National Cancer Institute, 2018. 110(8): p.
- Extracellular vesicles. Philos Halls Noot Lond B Biol Sci, 2018. 373(1737).

526 43. Samet, J.M., Lung Cancer, Smoking, and Obesity: It's Complicated. JN

527 National Cancer Institute, 2018. 110(8): p. 795-796.

528 44. S 527 National Cancer Institute, 2018. 110(8): p. 795-796.

528 44. Sin, S., et al., *Metabolic Syndrome and Risk of Lung Cancer: An Analysis of Korean National*

529 Health Insurance Corporation Database. J Clin Endocrinol Mational Cancer Institute, 2016. 110(0): p. 795-796.

528 44. Sin, S., et al., *Metabolic Syndrome and Risk of Lung*
 Health Insurance Corporation Database. J Clin Endoc

45. Li, M., et al., *Association of Metabolic Syn* Fraction Database. J Clin Endocrinol Metab, 2020. 105(11).

530 45. Li, M., et al., Association of Metabolic Syndrome With Risk of Lung Cancer: A Population-

531 Based Prospective Cohort Study. CHEST, 2024. 165(1): p. 213 Fream Insurance Corporation Database. J. Clin Endocrinol Metab, 2020. 105(11).

530 45. Li, M., et al., Association of Metabolic Syndrome With Risk of Lung Cancer: A

531 Based Prospective Cohort Study. CHEST, 2024. 165(1) Based Prospective Cohort Study. CHEST, 2024. 165(1): p. 215-223.

532 46. Yuan, Z., et al., Association between metabolic overweight

readmission risk in patients with lung cancer: A retrospective coho

2022. 51.

535 47.
-
- 533 47. Tobias, D.K., et al., *Body-mass index and mortality among adults with incident type*
535 47. Tobias, D.K., et al., *Body-mass index and mortality among adults with incident type*
536 *diabetes.* N Engl J Med, 2014
-
- Frame metabolic interaction between metabolic orthodoxy phenotypes and

Frame metabolic overweight and the set al., Body-mass index and mortality among adults with incident type 2

S35 47. Tobias, D.K., et al., Body-mass i 534 2022.51.
535 47. Tobias, D.K., et al., *Body-mass index and mortality among adults with incident type 2*
536 *diabetes.* N Engl J Med, 2014. 370(3): p. 233-44.
537 48. Tseng, C.H., *Diabetes but not insulin increases t*
- 2022. 31.
535 47. Tobias, D
536 *diabetes.*
537 48. Tseng, C.
538 *population*
539 49. Tseng, C.
540 Diabetes F
541 50. Pearson-S
542 *Observati* 536 *diabetes.* N Engl J Med, 2014. **370**(3): p. 233-44.

537 48. Tseng, C.H., *Diabetes but not insulin increases the risk of lung cancer: a Taiwanese

538 population-based study. PLoS One, 2014. 9(7): p. e101553.

539 49* 2035 diabetes. N Engl 3 Med, 2014. 370(3): p. 233-44.

537 48. Tseng, C.H., *Diabetes but not insulin increas*
 population-based study. PLoS One, 2014. 9(7): p.

539 49. Tseng, C.H., *Higher risk of mortality from lung*
 538 population-based study. PLoS One, 2014. 9(7): p. e101553.

539 49. Tseng, C.H., Higher risk of mortality from lung cancer in Taiwanese people with diabetes.

540 Diabetes Res Clin Pract, 2013. 102(3): p. 193-201.

541 Example 1933 population-based stady. PLOS One, 2014. 9(7): p. e101533.

539 49. Tseng, C.H., *Higher risk of mortality from lung cancer in*

540 Diabetes Res Clin Pract, 2013. 102(3): p. 193-201.

50. Pearson-Stuttard, J., 540 Diabetes Res Clin Pract, 2013. 102(3): p. 193-201.
541 50. Pearson-Stuttard, J., et al., *Type 2 Diabetes and Cancer: An Umbrella Review of*
542 *Observational and Mendelian Randomization Studies.* Cancer Epidemiol Bio Bradian Bandetes Res Chin Pract, 2013. 102(3): p. 133-201.

541 50. Pearson-Stuttard, J., et al., Type 2 Diabetes

542 Observational and Mendelian Randomization St

543 2021. 30(6): p. 1218-1228.

544 51. Yu, D., et al., O 542 Observational and Mendelian Randomization Studies. Cancer Epidemiol Biomarkers Prev,
543 2021. 30(6): p. 1218-1228.
544 51. Yu, D., et al., *Overall and Central Obesity and Risk of Lung Cancer: A Pooled Analysis. J Nat*
- 543 2021. 30(6): p. 1218-1228.
544 51. Yu, D., et al., *Overall and Central Obesity and Risk of Lung Cancer: A Pooled Analysis.* J Natl
545 Cancer Inst, 2018. 110(8): p. 831-842.
546 52. Hidayat, K., et al., *Abdominal Obe* 543 2021. 30(0). p. 1218-1228.
544 51. Yu, D., et al., Overall and C
545 Cancer Inst, 2018. 110(8): p
546 52. Hidayat, K., et al., *Abdomi*
547 Analysis of Prospective Stud
- 545 Cancer Inst, 2018. 110(8): p. 831-842.
546 52. Hidayat, K., et al., *Abdominal Obesity and Lung Cancer Risk: Systematic Review and Meta-*
547 Analysis of Prospective Studies. Nutrients, 2016. **8**(12).
22 545 Cancer Hist, 2018. 110(8): p. 831-842.
546 52. Hidayat, K., et al., *Abdominal Obesity*
547 Analysis of Prospective Studies. Nutrie Analysis of Prospective Studies. Nutrients, 2010. $\mathbf{G}(12)$.

It is made available under a CC-BY-NC-ND 4.0 International license.

- 549 Obesity Paradox in Lung Cancer. J Thorac Oncol, 2021. 16(8): p. 1333-1348.
550 54. Bhupathiraju, S.N. and F.B. Hu, *Epidemiology of Obesity and Diabetes and Their*
551 *Cardiovascular Complications*. Circ Res, 2016. 11 SERIM Paradox in Lang Cancer. J Historico, 2021. 19(6): p. 1553-1546.

550 S4. Bhupathiraju, S.N. and F.B. Hu, Epidemiology of Obesity and Dial

551 Cardiovascular Complications. Circ Res, 2016. 118(11): p. 1723-35.

552 S
- Cardiovascular Complications. Circ Res, 2016. 118(11): p. 1723-35.

552 55. Khandekar, M.J., P. Cohen, and B.M. Spiegelman, *Molecular mechanisms of cancer*

553 *development in obesity.* Nat Rev Cancer, 2011. 11(12): p. 8
-
-
-
- Cardiovascular Compineations. Circ Res, 2010. 110(11): p. 1723-35.

552 55. Khandekar, M.J., P. Cohen, and B.M. Spiegelman, *Molecular

development in obesity*. Nat Rev Cancer, 2011. 11(12): p. 886-95.

554 56. Fardet, A. development in obesity. Nat Rev Cancer, 2011. 11(12): p. 886-95.

554 56. Fardet, A. and E. Rock, *Chronic diseases are first associated with the degradation and*

555 arrore than calorie quantity. Eur J Nutr, 2022. 61(5): Example 1. The Cancer, 2011. 11(12): p. 886-95.

554 56. Fardet, A. and E. Rock, Chronic diseases are first associated

355 artificialization of food matrices rather than with food composit

356 more than calorie quantity. ortificialization of food matrices rather than with food composition: calorie quality matters

standard more than calorie quantity. Eur J Nutr, 2022. 61(5): p. 2239-2253.

557 57. Badoud, F., et al., Molecular insights int 556 more than calorie quantity. Eur J Nutr, 2022. 61(5): p. 2239-2253.
557 57. Badoud, F., et al., *Molecular insights into the role of white adipose tissue in metabolically*
558 unhealthy normal weight and metabolically h 557 57. Badoud, F., et al., *Molecular insights into the role of white adip*
558 unhealthy normal weight and metabolically healthy obese individual
559 748-58.
560 58. Karelis, A.D., et al., *Metabolic and body composition* 558 unhealthy normal weight and metabolically healthy obese individuals. Faseb j, 2015. 29(3): p.
559 748-58.
560 58. Karelis, A.D., et al., *Metabolic and body composition factors in subgroups of obesity: what do*
561 we
- Essand Marchiny normal weight and metabolically healthy obese individuals. Faseb j, 2013. 29(3): p.

559 748-58.

560 58. Karelis, A.D., et al., *Metabolic and body composition factors in subgroups of obesity: what do*

56 560 58. Karelis, *i*
561 *we know*
562 59. Cao, H.,
563 *risk: a m*
564 Figure Legends
565 Figure Legends
- 561 we know? J Clin Endocrinol Metab, 2004. **89**(6): p. 2569-75.
562 59. Cao, H., et al., *Association between circulating levels of IGF-1 and IGFBP-3 and lung cancer*
563 risk: a meta-analysis. PLoS One, 2012. 7(11): p. e we know? Sellin Endocrinol Metab, 2004. 89(6): p. 2565-75.

562 59. Cao, H., et al., Association between circulating levels of IG.

563 risk: a meta-analysis. PLoS One, 2012. 7(11): p. e49884.

564

565 Figure Legends

567 563 risk: a meta-analysis. PLoS One, 2012. 7(11): p. e49884.
564
565 Figure Legends
567 Figure 1: The relative contribution of food groups to the total diet (a) and to the subtotal of
568 UPF consumption in men (b) and wom

-
-
- Figure Legends

Figure Legends

Figure 1: The relative contribution of food groups to the to

UPF consumption in men (b) and women (c) in the

Figure 2: Non-linear relationship of UPF consumption in w

incidence among olde 565
566
567
568
569
570
571 566
567
568
569
570
571
572
573 567 Figure 1: The
568 UPF
569 Figure 2: Non
570 incide
571 Figure 3: Sub
572 can
573 olde Figure 1: The relative contribution of food groups to the total diet (a) and to the subtotal of
568 UPF consumption in men (b) and women (c) in the PLCO trial data.
569 Figure 2: Non-linear relationship of UPF consumption UPF consumption in men (b) and women (c) in the PLCO trial data.

569 Figure 2: Non-linear relationship of UPF consumption in weight ratio and lung

570 incidence among older adults participated in the PLCO trial, USA.

57 Figure 2: Non-linear relationship of UPF consumption in weight ratio and lung cancer
incidence among older adults participated in the PLCO trial, USA.
Figure 3: Subgroup analysis for the association between UPF consumption 570 incidence among older adults participated in the PLCO trial, USA.
571 Figure 3: Subgroup analysis for the association between UPF consumption
572 cancer incident stratified by demographic, lifestyle and baseline
573 ol 571 Figure 3: Subgroup analysis for the association between UPF consumption and risk of lung
cancer incident stratified by demographic, lifestyle and baseline comorbidities in
older adults enrolled in the PLCO trial, the i 572 cancer incident stratified by demographic, lifestyle and baseline comorbidities in
older adults enrolled in the PLCO trial, the in USA]. The model was adjusted for
23 older adults enrolled in the PLCO trial, the in USA]. The model was adjusted for
23

medRxiv preprint doi: [https://doi.org/10.1101/2024.09.27.24314515;](https://doi.org/10.1101/2024.09.27.24314515) this version posted September 30, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 574 covariates mentioned in Table 2 footnote. BMI: body mass index; HR: hazard
575 ratio; UPF: ultra-processed foods.
576
577
- 575 ratio; UPF: ultra-processed foods.
576
577
578
-
-
-
- 577
578
579 578
579
- 578

American Indian

. [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) It is made available under a

. [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) It is made available under a

It is made available under a CC-BY-NC-ND 4.0 International license

. [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) It is made available under a

It is made available under a CC-BY-NC-ND 4.0 International license

medRxiv preprint doi: https://doi.org/10.1101/2024.09.27.24314515; this version posted September 30, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant is the presult of the authory funder medical state to display is the author/funder, she seeked and prepriated by peer redsignation in perception the preprint in perceptive defined by peer redsignation of α and α is t me copyright holder for this version 2011. 1017/2024. [;](https://doi.org/10.1101/2024.09.27.24314515) https://doi.org/10.1101/2024. ; https://doi.org/10.1101/2024. ; https://doi.org/10.1101/2024. ; https://doi.org/10.1101/2024. ; https://doi.org/10.1101/2024.09.27.243 It is made available under a CC-BY-NC-ND 4.0 International license . [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) It is made available under a

Other includes unemployed, disabled, and extended sick leave; SD: standard deviation.

. [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) It is made available under a

It is made available under a CC-BY-NC-ND 4.0 International license

. [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) It is made available under a

It is made available under a CC-BY-NC-ND 4.0 International license

. [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) It is made available under a

It is made available under a CC-BY-NC-ND 4.0 International license

Model 5 Ref 0.92(0.78,1.08) 0.98(0.83,1.15) 0.96(0.82, 1.13) 0.98(0.83,1.15) 0.32 0.98(0.85, 1.13) 0.44 Competing risk Regression

Ref 0.92(0.78,1.09) 0.97(0.82,1.14) 0.95(0.81,1.12) 0.95(0.81,1.12) 0.35

^a cumulative incidence rate per 10,000 person-years; * represents significant at p-value <0.05; and *** significant at p-linear < 0.001.

Model 1: unadjusted model.

Model 2: Adjusted for Age and sex.

Model 3: adjusted for model 2 plus study arm, race, marital status, education, occupation, smoking, BMI, family history of lung cancer and alcohol consumption.

Model 4: Adjusted for model 3 plus chronic comorbidity (diabetes, hypertension, heart attack, stroke, chronic bronchitis, and emphysema).

Model 5: Additionally adjusted for total dietary energy plus model 4 and excluding dietary alcohol consumption.

Table 3: Adjusted HRs (95% CI) and additive interaction between UPF consumption and diabetes status for the risk of LC in US (n =

 $91,453$ ^a

AP: Attributable Proportion; CI: Confidence Interval; HR: Hazard Ratio; LC: Lung Cancer; RERI: Relative Excess Risk due to Interaction;

SI: Synergy Index; UPF: Ultra-processed Food.

^a Models were adjusted for age, sex, ethnicity, study arm, marital status, education, occupation, cigarette smoking, BMI, family history of lung cancer, history of hypertension, heart attack, chronic bronchitis, emphysema, alcohol intake and total dietary calory intake.

^b Percentage of UPF (%gm/day) categorised as high and low based on the mean intake of UPF which was ≥ 31.2 % for high and < 31.2% for low).

. [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) It is made available under a

It is made available under a CC-BY-NC-ND 4.0 International license

. [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) It is made available under a

It is made available under a CC-BY-NC-ND 4.0 International license

Table 4: Interaction between UPF consumption and diabetes for the risk of lung cancer among adults using additive hazard models in comparison with Cox proportional hazard models, US ($n = 91,453$).

^a Models were adjusted for age, sex, race, study arm, marital status, education, occupation, family income, smoking, BMI, physical activity, family history of lung cancer, history of hypertension, heart attack, chronic bronchitis, emphysema, alcohol intake and total dietary calory intake.

^b Percentage of UPF (%gm/day) categorised as high and low based on the mean intake of UPF which was ≥ 31.2 % for high and < 31.2% for low).

. [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) It is made available under a

It is made available under a CC-BY-NC-ND 4.0 International license

. [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) It is made available under a

 $*$ Indicates covariates significant at p-value < 0.05, and $**$ at p-value < 0.01.